Purple Biotech (PPBT) 20-F 26 Mar 19 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document and Entity Information [Abstract]
Entity Registrant Name	Kitov Pharma Ltd.
Entity Central Index Key	0001614744
Amendment Flag	false
Trading Symbol	KTOV
Current Fiscal Year End Date	--12-31
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	16,009,264

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 5,163	$ 3,947
Short term deposits	1,521	3,488
Other current assets	1,830	548
Total current assets	8,514	7,983
Fixed assets, net	37	28
Intangible assets	6,172	6,172
Total assets	14,723	14,183
Liabilities
Accounts payable	705	215
Other payables	2,055	1,746	[1]
Derivative instruments	554	2,012
Total current liabilities	3,314	3,973
Non-current liabilities
Derivative instruments		1,030
Post-employment benefit liabilities	405	492
Total non - current liabilities	405	1,522
Equity
Share capital, no par value
Share premium	44,597	35,979
Receipts on account of warrants	7,982	7,415
Capital reserve for share-based payments	1,714	1,725
Capital reserve from transactions with related parties	761	761
Capital reserve from transactions with non- controlling interest	(859)
Accumulated loss	(43,672)	(38,472)	[1]
Equity attributable to owners of the Company	10,523	7,408
Non-controlling interests	481	1,280
Total equity	11,004	8,688
Total liabilities and equity	$ 14,723	$ 14,183
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Profit or loss [abstract]
Revenues	$ 1,000	$ 100	[1]
Research and development expenses	5,268	4,640		4,180
General and administrative expenses	5,195	6,397	[1]	3,003
Reimbursement of legal fees	(743)
Other expenses (income)	(894)	1,029
Total operating expenses	8,826	12,066		7,183
Operating Loss	7,826	11,966	[1]	7,183
Net change in fair value of derivatives	(2,740)	1,049		5,019
Finance expense	576	26		61
Finance income	(93)	(128)		(138)
Finance expenses (income), net	(2,257)	947		4,942
Loss for the year	5,569	12,913	[1]	12,125
Other comprehensive loss
Re-measurement of defined benefit liability		95		21
Total comprehensive loss for the year	5,569	13,008	[1]	12,146
Loss attributable to:
Owners of the Company	5,200	12,177	[1]	12,125
Non-controlling interests	369	736
Total Loss attributable	5,569	12,913	[1]	12,125
Total comprehensive loss attributable to:
Owners of the Company	5,200	12,272	[1]	12,146
Non-controlling interests	369	736
Non-controlling interests	$ 5,569	$ 13,008	[1]	$ 12,146
Loss per share data
Basic and diluted loss per share - USD	$ 0.39	$ 1.37	[2]	$ 2.11	[2]
Number of shares used in calculating basic and diluted loss per share	14,205,301	9,456,952	[2]	5,755,747	[2]
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).
[2]	Restated to reflect a 20:1 reverse share split, that took place in January 2019, see Note 9A.

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total		Share Capital	Share premium	Receipts on account of warrants	Capital reserve for share-based payments	Capital reserve from transactions with related parties	Capital reserve from transactions with Non-controlling interest [Member]	Accumulated loss		Total equity	Non-controlling interests
Balance at Dec. 31, 2015	$ 9,429			$ 22,159	$ 27	$ 536	$ 761		$ (14,054)
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs	5,222			5,222
Exercise of warrants	302			302
Share-based payments	400			103		297
Transfer of derivative instrument from liability to equity	7,388				7,388
Issuance of warrants, net of issuance costs	2,517				2,517
Share issuance due to a development agreement	250			500		(250)
Exercise of warrants (series B)	23			2,540	(2,517)
Total transactions with owners of the Company	16,102			8,667	7,388	47
Comprehensive loss for the year:
Loss for the year	(12,125)								(12,125)
Other comprehensive loss	(21)								(21)
Total comprehensive loss for the year	(12,146)								(12,146)
Balance at Dec. 31, 2016	13,385			30,826	7,415	583	761		(26,200)	[1]	$ 13,385
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs	2,174			2,174						[1]	2,174
Issuance of shares due to RSUs vesting				1,083		(1,083)
Share issuance due to an acquisition of a subsidiary (see Note 5)	3,816			1,800						[1]	1,800	2,016
Share-based payments	2,321			96		2,225				[1]	2,321
Total transactions with owners of the Company	8,311			5,153		1,142				[1]	6,295	2,016
Comprehensive loss for the year:
Loss for the year	(12,913)	[1]							(12,177)	[1]	(12,177)	(736)
Other comprehensive loss	95								(95)	[1]	(95)
Total comprehensive loss for the year	(13,008)	[1]							(12,272)	[1]	(12,272)	(736)
Balance at Dec. 31, 2017	8,688			35,979	7,415	1,725	761		(38,472)	[1]	7,408	1,280
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs	4,276			4,276							4,276
Issuance of shares due to RSUs vesting				299		(299)
Exercise of warrants	2,133			2,133							2,133
Share issuance due to an acquisition of a subsidiary (see Note 5)	136			1,856				(859)			997	(861)
Share-based payments	773			54		288					342	431
Transfer of derivative instrument from liability to equity	567				567						567
Total transactions with owners of the Company	7,885			8,618	567	(11)		(859)			8,315	(430)
Comprehensive loss for the year:
Loss for the year	(5,569)
Other comprehensive loss
Total comprehensive loss for the year	(5,569)								(5,200)		(5,200)	(369)
Balance at Dec. 31, 2018	$ 11,004			$ 44,597	$ 7,982	$ 1,714	$ 761	$ (859)	$ (43,672)		$ 10,523	$ 481
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Cash flows from operating activities:
Loss for the year	$ (5,569)	$ (12,913)	[1]	$ (12,125)
Adjustments:
Depreciation	7	4		2
Finance expenses (income), net	(2,257)	947		4,942
Share-based payments	773	2,308		400
Expenses (income) in regards with settlement with a minority shareholder of a subsidiary (see Note 5B)	(894)	1,000
Expenses in regard to a strategic cooperation agreement				250
Total adjustments	(7,940)	(8,654)		(6,531)
Changes in assets and liabilities:
Changes in other receivables	(1,111)	(273)
Changes in accounts payable	393	(491)		(138)
Changes in other payables	241	650	[1]	357
Changes in post-employment benefit liabilities	(63)	141		50
Changes in assets and liabilities, total	(540)	27		269
Net cash used in operating activities	(8,480)	(8,627)		(6,262)
Cash flows from investing activities:
Acquisition of a subsidiary (see Note 5)		(1,732)
Decrease (increase) in short term deposits	1,967	4,411		(7,899)
Interest received	93	106		138
Acquisition of fixed assets	(16)	(13)		(10)
Net cash provided by (used in) investing activities	2,044	2,772		(7,771)
Cash flows from financing activities:
Repayment of loans from related parties		(130)
Short-term credit from bank		(16)
Proceeds from issuance of ADSs	4,683	2,419		6,287
Share and ADS issuance expenses paid	(407)	(245)		(1,065)
Proceeds from issuance of warrants	3,467	1,107		5,713
Warrants issuance expenses paid	(301)	(114)		(968)
Receipts from warrant exercise	515			325
Interest paid	(169)	(26)		(6)
Net cash provided by financing activities:	7,788	2,995		10,286
Net increase (decrease) in cash and cash equivalents	1,352	(2,860)		(3,747)
Cash and cash equivalents at the beginning of the year	3,947	6,758		10,558
Effect of translation adjustments on cash	(136)	49		(53)
Cash and cash equivalents at end of the year	$ 5,163	$ 3,947		$ 6,758
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

General

General	12 Months Ended
	Dec. 31, 2018
General [Abstract]
General	Note 1 - General Reporting entity Kitov Pharma Ltd. (hereinafter: “the Company The Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange since September 1978. In October 2012, the Company disposed of all of its previous operations, and in July 2013, the Company acquired shares of Kitov Pharmaceuticals Ltd. (hereinafter: “ Kitov “the Acquisition” In January 2018, the Company changed its name to Kitov Pharma Ltd. The Company’s securities (American Depository Shares (“ADS”) as well as Series A warrants) were listed for trading on the NASDAQ in November 2015. Each ADS represents 1 ordinary share with no par value following a reverse split in effect from January 4, 2019 (see note 9A). Each warrant enables the purchase of 1 ADS. In December 2017, the Company completed its merger with Kitov, with the Company remaining as the surviving entity. The effective date of the merger was December 31, 2017. The Company’s address is One Azrieli Center, Round Tower, 132 Menachem Begin Road, Tel-Aviv 6701101 Israel. In January 2017, the Company acquired the majority of shares of TyrNovo Ltd. (hereinafter: “ TyrNovo The Company together with TyrNovo are referred to, in these financial statements, as “ the Group Since incorporation through December 31, 2018, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated deficit of USD 43.7 million. The Group has financed its operations mainly through private and public financing rounds. Through December 31, 2018, the Company raised a total of USD 39.7 million net, and in January 2019, the Company raised additional USD 5.4 million net. Management anticipates that its existing capital resources will be adequate to satisfy liquidity requirements for the next 12 months. Subsequently, management’s plans include pursuing alternative financing arrangements or reducing expenditures as necessary to meet the Company’s future cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity.

Basis of Preparation of the Fin

Basis of Preparation of the Financial Statements	12 Months Ended
	Dec. 31, 2018
Basis of Preparation of the Financial Statements [Abstract]
Basis of Preparation of the Financial Statements	Note 2 - Basis of Preparation of the Financial Statements A. Statement of compliance with International Financial Reporting Standards The Group has prepared the financial statements in accordance with International Financial Reporting Standards (hereinafter: “IFRS”), as issued by the International Accounting Standard Board (“IASB”). These financial statements have been approved by the board of directors on March 25, 2019. B. Functional and presentation currency These financial statements are presented in US dollars (USD), which is the Group’s functional currency, rounded to the nearest one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates. C. Use of estimates and judgment The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group’s financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in the following notes: Estimate Principal assumptions Possible effects Reference Fair value measurement of non-trading derivatives Unobservable inputs used in the valuation model including standard deviation and discount rates Profit or loss from a change in the fair value of derivative financial instruments For information on a sensitivity analysis of level 3 financial instruments carried at fair value see Note 20B regarding financial instruments Assessment of probability of contingent liabilities Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees Reversal or creation of a provision for a claim For information on the Company’s exposure to claims see Note 12B regarding contingent liabilities Fair value measurement The Group’s management regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Group Audit Committee. When measuring the fair value of an asset or liability, the Group uses market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: - Level 1: quoted prices in active markets for identical assets or liabilities. - Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. - Level 3: inputs for the asset or liability that are not based on observable market data. If the inputs used to measure the fair value of an asset or a liability might be categorized in different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. Further information about the assumptions made in measuring fair value of share based payments and derivative instruments are included in Note 10 and Note 20, respectively. D. Exchange rates and linkage bases Balances in foreign currency or linked thereto are included in the financial statements at the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position date. Data on exchange rates are as follows: Representative exchange rate of USD (NIS/USD 1) Date of financial statements: December 31, 2018 3.748 December 31, 2017 3.467 December 31, 2016 3.845 Changes in exchange rates for the year ended: % December 31, 2018 8.1 December 31, 2017 (9.8 ) December 31, 2016 (1.5 ) E. Initial application of new standards, amendments to standards and interpretations As from January 1, 2018 the Group applies the new standards and amendments to standards described below. The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective. (1) IFRS 9 (2014), Financial Instruments As from January 1, 2018 the Group applies IFRS 9 (2014), Financial Instruments Financial Instruments: Recognition and Measurement (in this item “IAS 39”). Additionally, following the application of IFRS 9, the Group has adopted consequential amendments to IFRS 7, Financial Instruments: Disclosures Presentation of Financial Statements The Group has chosen to apply the standard as from January 1, 2018 (in this item: “date of initial application”) without amendment of the comparative data, the application of this standard has no material impact on the Group’s financial statements. For further information on how the Group classifies and measures financial instruments and accounts for related gains and losses under IFRS 9, see Note 3C. (2) IFRS 15, Revenue from Contracts with Customers As from January 1, 2018 the Group applies, IFRS 15 Revenue from Contracts with customers (1) Identifying the contract with the customer. (2) Identifying distinct performance obligations in the contract. (3) Determining the transaction price. (4) Allocating the transaction price to distinct performance obligations. (5) Recognizing revenue when the performance obligations are satisfied. Under IFRS 15, revenue is recognized at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to a customer. The standard requires entities to exercise judgement, taking into consideration all of the relevant facts and circumstances when applying each step of the model to contracts with their customers. For further information on how the Group recognize revenue under IFRS 15, see Note 3I. The Group adopted IFRS 15 using the full retrospective method of adoption. The effect of adopting IFRS 15 is, as follows: Impact on the statement of financial position as of December 31, 2017: According to the previous According to policy The change IFRS 15 USD thousands USD thousands USD thousands Deferred income 95 (95 ) - Accumulated loss (38,567 ) 95 (38,472 ) Impact on the statement of operations for the year ended December 31, 2017: According to the previous According to policy The change IFRS 15 USD thousands USD thousands USD thousands Revenues - (100 ) (100 ) General and administrative expenses 6,392 5 6,397 Operating Loss 12,061 (95 ) 11,966 Loss for the year 13,008 (95 ) 12,913 Impact on basic and diluted loss per share data : Basic and diluted loss per share -USD (*) (0.02 ) 1.37 (*) Restated to reflect a 20:1 reverse share split, that took place in January 2019, see Note 9A. The nature of these adjustments are described below: The Group’s revenues are derived from license and commercialization agreements. The impact from the adoption of IFRS 15 Revenue from Contracts with Customers (3) IFRIC 22, Foreign Currency Transactions and Advance Consideration The interpretation provides that the transaction date for the purpose of determining the exchange rate for recording a foreign currency transaction that includes advanced consideration is the date of initial recognition of the non-monetary asset/liability from the prepayment. If there are multiple payments or receipts in advance, a transaction date is established for each payment or receipt. As from January 1, 2018 the Group applies IFRIC 22. The Group has examined the effects of applying IFRIC 22, and in its opinion there is an immaterial effect on the financial statements.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 3 - Significant Accounting Policies The accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements: A. Basis of consolidation 1. Business combination The Group accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. 4. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. B. Foreign currency transactions Transactions in foreign currency are translated to the functional currency of the Group at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currency as of the reporting date are translated into the functional currency at the exchange rate as of the said date. Exchange rate differences with respect to monetary items are the differences between the amortized cost in the functional currency as of the start of the year, adjusted for the effective interest during the year, and the amortized cost in foreign currency, translated at the exchange rate as of the end of the year. Non-monetary items denominated in foreign currency and measured at historical cost, are translated using the exchange rate as of the transaction date. Exchange rate differences arising from translation into the functional currency are recognized on the statement of operations as financial expenses. C. Financial instruments 1. Non-Derivative financial instruments a. Non-derivative financial assets – policy applicable as from January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: assets at amortized cost; assets at fair value through other comprehensive income – investments in debt instruments; assets at fair value through other comprehensive income – investments in equity instruments; or assets at fair value through profit or loss. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. b. Non-derivative financial assets – policy applicable before January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes receivables and deposits on the date that they are created. All other financial assets acquired in a regular way purchase, are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument, meaning on the date the Group undertook to purchase or sell the asset. Non-derivative financial assets include: cash and cash equivalents, short term deposits and other receivables. Cash and cash equivalents include cash balances available for immediate use and call deposits. Cash equivalents include short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. c. Non-derivative financial liabilities Non-derivative financial liabilities include: accounts payables and other accounts payable. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. d. Derivative financial liabilities The Group holds derivative financial instruments that do not serve for hedging purposes. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation, and classified as level 3. D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve also plans or designs for the production of new or substantially improved products and processes. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life. 4. Timing of impairment testing Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains goodwill, or intangible assets that have indefinite useful lives or are unavailable for use. E. Loss per share The Group presents loss per share data for its ordinary share capital. Loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period. F. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance companies or with funds managed by a trustee, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Other long-term employee benefits The Group’s net obligation in respect of long-term employee benefits plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. G. Share-based payment transactions The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. H. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. I. Revenue The Group recognizes revenue from upfront and milestone payments at the point in time the milestone criteria is highly probable to be met and collectability is probable The Group will recognize sales based on royalty income, earned through a license, when the underlying sales will occur. Identifying the contract The Group accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Group can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Group can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Group is entitled to in exchange for the goods or services transferred to the customer, will be collected. For the purpose of section (e) the Group examines, inter alia, the percentage of the advance payments received and the spread of the contractual payments, past experience with the customer and the status and existence of sufficient collateral. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Group has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. Identifying performance obligations On the contract’s inception date the Group assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer one of the following: (a) Goods or services (or a bundle of goods or services) that are distinct; or (b) A series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. The Group identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Group’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. In order to examine whether a promise to transfer goods or services is separately identifiable, the Group examines whether it is providing a significant service of integrating the goods or services with other goods or services promised in the contract into one integrated outcome that is the purpose of the contract. Determining the transaction price The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for the license and commercialization agreement. The Group takes into account the effects of all the following elements when determining the transaction price: variable consideration, the existence of a significant financing component, non-cash consideration, and consideration payable to the customer. Variable consideration The Group includes variable consideration, or part of it, in the transaction price only when it is highly probable that its inclusion will not result in a significant revenue reversal in the future when the uncertainty has been subsequently resolved. At the end of each reporting period and if necessary, the Group revises the amount of the variable consideration included in the transaction price. Right to use and right to access To determine whether the Group’s promise to grant a license provides a customer with either a right to access the Group’s IP or a right-to-use the Group’s IP, the Group considers whether a customer can direct the use of, and obtain substantially all of the remaining benefits from, a license at the point in time at which the license is granted. A license is considered a “right-to-use” license when the customer maintains control of the IP upon its transfer. However, if the grantor of the license maintains involvement with the IP after its transfer, and the customer cannot direct the use of, and obtain substantially all of the remaining benefits from the license, then the license is considered a right-to-access license. J. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, and income from short term deposits. Finance expenses include loss from exchange rate differences. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received and interest paid are presented as part of cash flows from financing activities. K. Equity Incremental costs directly attributable to an expected issuance of an instrument that will be classified as equity are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from the equity upon the initial recognition of the equity instruments, or are expensed as financing expenses in the statement of operations when the issuance is no longer expected to take place. L. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. M. Deferred tax A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable profits will be available against which they can be utilized. N. New standards and interpretations not yet adopted (1) IFRS 16, Leases The standard replaces IAS 17, Leases In addition, IFRS 16 permits the lessee to apply the definition of the term lease according to one of the following two alternatives consistently for all leases: retrospective application for all the lease agreements, which means reassessing the existence of a lease for each separate contract, or alternatively to apply a practical expedient that permits continuing with the assessment made regarding existence of a lease based on the guidance in IAS 17, Leases Determining whether an Arrangement contains a Lease IFRS 16 is applicable for annual periods as of January 1, 2019. IFRS 16 includes various alternative transitional provisions, so that companies can choose between one of the following alternatives at initial application consistently for all leases: full retrospective application or recognizing a cumulative effect, which means application (with the possibility of certain practical expedients) as from the mandatory effective date with an adjustment to the balance of retained earnings at that date. Method of application and expected effects The Group adopted IFRS 16 as from January 1, 2019 using the cumulative effect method as at January 1, 2019. Expedients: (1) Not applying the requirement to recognize a right-of-use asset and a lease liability in respect of short-term leases of up to one year. (2) Not separating non-lease components from lease components and instead accounting for all the lease components and related non-lease components as a single lease component. (3) Not applying the requirement to recognize a right-of-use asset and a lease liability in respect of leases where the underlying asset has a low value. (4) Applying a single discount rate to a portfolio of leases with reasonably similar characteristics. Expected effects: The Group plans to elect to apply the transitional provision of recognizing a lease liability at the date of initial application, for all the leases that award it control over the use of identified assets for a specified period of time, and except for when the Group has elected to apply the standard’s expedients as aforesaid, according to the present value of the future lease payments discounted at the incremental borrowing rate of the lessee at that date, and concurrently recognizing a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments that were recognized as an asset or liability before the date of initial application. Therefore, application of the standard is not expected to have an effect on the balance of retained earnings at the date of initial application. These changes are expected to result in an increase of USD 1.2 million in the balance of right-of-use assets at the date of initial application and an increase of USD 1.2 million in the balance of the lease liability at the date of initial application. Accordingly, depreciation and amortization expenses will be recognized in subsequent periods in respect of the right-of-use asset, and the need for recognizing impairment of the right-of-use asset will be examined in accordance with IAS 36. Furthermore, financing expenses will be recognized in respect of the lease liability. Therefore, as from the date of initial application and in subsequent periods, depreciation expenses and financing expenses will be recognized instead of lease expenses relating to assets leased under an operating lease, which were presented as part of the general and administrative expenses item in the income statement. In addition, the nominal discount rate used for measuring the lease liability is 8%.

Operating Segments

Operating Segments	12 Months Ended
	Dec. 31, 2018
Operating Segments [Abstract]
Operating Segments	Note 4 - Operating Segments Since 2018 the chief operating decision marker (CODM) has started to review the results of two reportable segments, as described below, which form the Group’s strategic business units. The strategic business units offer different products and services and the allocation of resources and evaluation of performance are managed separately because they require different technology and marketing strategies. For each of the strategic business units, the Group’s CODM reviews internal management reports on at least a quarterly basis. The following summary describes the operations in each of the Group’s operating segments: ● Pain and Hypertension – Includes development and marketing of Consensi TM ● Oncology – Includes development of a small molecule that has demonstrated in pre-clinical studies the potential to overcome resistance to multiple anti-cancer drugs. The accounting policies of the operating segments are the same as described in Note 3 regarding significant accounting policies. Performance is measured based on segment operating results as included in reports that are regularly reviewed by the chief operating decision maker. Segment results are used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries. Segment results reported to the chief operating decision maker include items directly attributable to a segment on a reasonable basis. Information about reportable segments Information regarding the results of each reportable segment is included below. For the year ended December 31, 2018 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 1,000 - 1,000 - 1,000 Research and development expenses 2,185 2,537 4,722 546 5,268 Operating loss 4,730 3,217 7,947 (121 ) 7,826 Finance income, net (2,257 ) Loss for the year 5,569 For the year ended December 31, 2017 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 100 - 100 - 100 Research and development expenses 2,603 1,328 3,931 709 4,640 Operating loss 6,674 1,951 8,625 3,341 11,966 Finance expenses, net 947 Loss for the year 12,913 (*) Includes employees share based expenses and other expenses/income related to rights granted to Taoz. Information on geographical segments In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers. Revenues in 2018 were derived from one customer and revenues in 2017 were derived from a different one customer, in both years from the far-east. For further information see Note 13.

Subsidiary

Subsidiary	12 Months Ended
	Dec. 31, 2018
Subsidiary [Abstract]
Subsidiary	Note 5 - Subsidiary A. On January 13, 2017, the Company completed its acquisition from Goldman Hirsh Partners Ltd (“GHP”) of a controlling interest in TyrNovo, a privately-owned Israeli company, which is developing NT-219, a small molecule that has demonstrated in pre-clinical studies the potential to overcome resistance to multiple anti-cancer drugs. Pursuant to the terms of the transaction, the Company issued to GHP 564,625 of its Ordinary Shares (the “Consideration Shares”) and paid GHP aggregate cash proceeds of approximately USD 2 million (the “Cash Consideration”) in exchange for 9,570 Ordinary Shares in TyrNovo, that represented approximately 65% of TyrNovo’s shares. In addition, the Company was assigned a loan in the amount of USD 101 thousand which had been made by GHP to TyrNovo, (the “TyrNovo Acquisition”). USD 167 thousand of the Cash Consideration was held back by the Company pending the fulfillment of certain conditions as agreed to between the Company and GHP. On February 4, 2019, the Company and GHP signed an agreement, according to which the Company paid to GHP USD 91 thousand and the remaining USD 76 thousand are retained by the Company to cover any future claims it might have with regards of any matter the above amount was withheld for. The acquisition was accounted for as an asset purchase as it does not meet the definition of a business combination in accordance with IFRS 3. (1) Consideration The following summarizes the acquisition date fair value of each major class of consideration: USD thousands Cash 2,000 Equity instruments issued (564,625 Ordinary Shares) (1) 1,800 Assignment of loan to the Company (101 ) Total consideration transferred 3,699 (1) The fair value of the Ordinary Shares issued was based on the listed share price of the Group on January 11, 2017 of approximately USD 3.19 per share. (2) Identifiable assets acquired and liabilities assumed The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition: USD thousands Current assets 21 Fixed assets, net 3 Intangible assets (2) 6,172 Short-term credit from bank (16 ) Trade payables (123 ) Other payables (212 ) Long-term related parties (130 ) Total net identifiable assets 5,715 (2) In-process research and development Purchased in-process research and development expense represents the value assigned to research and development projects, which were commenced but not yet completed at the date of acquisition. Technological feasibility for these projects has not been established and they have no alternative future use in research and development activities or otherwise. B. Settlement with a minority shareholder On February 9, 2017, subsequent to the acquisition of TyrNovo, the Company, TyrNovo and Taoz - Company for Management and Holdings of Companies Ltd. (“Taoz”), a shareholder owning at that time approximately 4% of TyrNovo, entered into a settlement arrangement in response to a motion filed by Taoz on January 19, 2017. Pursuant to the settlement arrangement, the parties agreed, among other matters, as follows: Taoz was entitled to be issued an additional 77 ordinary shares of TyrNovo, representing 0.5% of the issued and outstanding share capital of TyrNovo immediately following this issuance. The shares were issued in February 2017 and were measured at a fair value of USD 29 thousand. Taoz had the right during a defined period to invest an additional USD 1,750,000 (the “Deferred Investment”) by way of convertible loans, with conversion terms defined under various circumstances, including the possibility of conversion at a price per share reflecting a 30% discount off the price per share paid in a subsequent financing round, and the possibility of conversion at a price per TyrNovo share reflecting a TyrNovo company valuation of USD 13,500,000. In the event that a defined milestone is achieved, and Taoz did not invest the Deferred Investment, then the Company has the right to acquire all of Taoz’s holdings in TyrNovo at a price per share of USD 476.48. The Company provided to Taoz a put option to sell to the Company up to 50% of the TyrNovo shares issued to Taoz, exercisable during a period of 90 days from the publication by TyrNovo of the results of Phase I clinical trials, for a price per TyrNovo share equal to USD 1,600, either in ordinary shares of the Company or, at the Company’ sole discretion, in cash; upon the expiration of the 90 day exercise period, the put option, if not exercised by Taoz, shall expire and no longer be valid. The rights granted to Taoz by the Company were valued at the date of agreement at USD 1,000 thousand and were charged to Other Expenses. The value of these rights as of December 31, 2017 was estimated at USD 1,030 thousand. The net change in value of this liability in the amount of USD 30 thousand was charged to Finance Expenses, as well as other expenses in the amount of USD 29 thousand value of shares issued to Taoz in the financial statements for the year ended December 31, 2017. Regarding Valuation techniques and significant unobservable inputs, see Note 20B. In regards with the acquisition of Taoz’s shares in TyrNovo, see Note 5C below. In October 2017, the Company signed an agreement for the acquisition of an additional 27% stake in TyrNovo (the “Newly Acquired TyrNovo Shares”), from a group of unaffiliated minority shareholders of TyrNovo, who collectively held 4,024 ordinary shares, or approximately 27%, of TyrNovo. In exchange for these Newly Acquired TyrNovo Shares, the Company issued to these unaffiliated minority shareholders of TyrNovo, in aggregate, 658,484 newly issued ordinary shares of the Company, which, at that time, represented approximately 6% of the Company’s issued and outstanding share capital . The closing of this transaction took place on March 15, 2018, following which the Company held approximately 91.9% of TyrNovo’s issued and outstanding ordinary shares. The carrying amount of TyrNovo’s net assets in the consolidated financial statements on the date of the acquisition was USD 2,821 thousand. The Group recognized a decrease in non-controlling interests of USD 768 thousand, an increase in share premium of USD 1,483 thousand and a decrease in a capital reserve for transactions with non-controlling interest of USD 715 thousand. C. In June 2018, the Company signed an agreement with a minority shareholder in TyrNovo, Taoz, for the acquisition of its holding in TyrNovo, which was approximately 4.1% of TyrNovo’s share capital. In exchange for these shares and for the waiving of investment rights and put options it was previously granted, which are described in Note 5B, the Company issued to Taoz 140,845 newly issued ordinary shares of the Company. The fair value of the shares issued as consideration for the acquisition of TyrNovo Shares amounted to USD 237 thousand. The fair value of the shares issued in consideration for waving the rights amounted to USD 136 thousand. As part of the agreement, the Company committed to register the newly issued shares for trading. The registration statement, registering the Company’s ADSs representing the newly issued shares for trading, was declared effective by the SEC as of August 8, 2018. In accordance with the agreement, the Company paid to Taoz in cash the difference between the share price of Kitov’s shares on the closing date to that on the registration date, which amounted to USD 160 thousand. The cash payment was recorded to finance expenses. The carrying amount of TyrNovo’s net assets in the consolidated financial statements on the date of the acquisition was USD 1,977 thousand. The Group recognized a decrease in non-controlling interests of USD 93 thousand, an increase in share premium of USD 237 thousand and a decrease in a capital reserve for transactions with non-controlling interest of USD 144 thousand. In addition, the Company derecognized the derivative liability of USD 1,030 thousand, recognized an amount of USD 894 thousand as other income and an increase in share premium of USD 136 thousand deriving from the waiving of the rights, as described above. The closing of this transaction took place on June 15, 2018, following which the Company held approximately 97.4% of TyrNovo’s issued and outstanding ordinary shares. D. Non-controlling interests Non-controlling interests are presented based on their proportionate interest in the recognized amount of the assets and liabilities of TyrNovo. E. The following is condensed information regarding TyrNovo: Amounts provided by the Company to the subsidiary Incorporated and Group’s ownership equity Company’s direct ownership of equity Loans Total investment in subsidiary USD thousands TyrNovo Ltd. Israel 97.6 % 97.6 % (2,366 ) 2,055

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 6 - Cash and Cash Equivalents As of December 31 2018 2017 USD thousands Balance in USD 4,410 3,322 Balance in other currencies 753 625 Total cash and cash equivalents 5,163 3,947

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2018
Other Current Assets [Abstract]
Other Current Assets	Note 7 - Other Current Assets As of December 31 2018 2017 USD thousands Government authorities 81 171 Reimbursement of legal fees receivable 743 - Prepaid fee to the Food and Drug Administration 930 - Prepaid expenses and other receivables 76 (*)377 Total other current assets 1,830 548 (*) Including an amount of USD 166 thousand, representing deposits entrusted to Israeli court on behalf of related parties pursuant to an indemnification obligation of the Company, in respect of an investigation of the Israeli Security Authority against the Company. See also Note 12B.

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2018
Other Payables [Abstract]
Other Payables	Note 8 - Other Payables As of December 31 2018 2017 USD thousands Due to related parties – payroll related 910 1,059 Due to GHP (Note 5A) 167 167 Accrued expenses 852 326 Government authorities 65 107 Payroll related payables 61 87 2,055 1,746

Equity

Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Equity	Note 9 - Equity A. On December 19, 2018 in a shareholders’ general meeting, it was resolved to consolidate the Company’s authorized and paid-in share capital in a 20:1 ratio, in a way that every 20 shares with no par value were consolidated into one share with no par value. The said reverse share split took place on January 4, 2019. Following the reverse share split, the Company’s authorized share capital is 250,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class. In these financial statements, all numbers of shares reflect the reverse share split retrospectively. B. The Company’s share capital As of December 31, 2018 As of December 31, 2017 Number of shares in thousands Authorized Issued and paid-in Authorized Issued and paid-in Ordinary shares, no par value 250,000 16,009 250,000 11,222 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 - C. Changes in share capital during the year For the year ended December 31 2018 2017 2016 Number of shares in thousands Issued as at January 1 11,222 7,662 3,888 Issuance of ADSs (See D below) 3,260 2,432 2,379 Issuance of shares (See Note 5) 799 565 - Share issuance deriving from a development agreement (See E6 below) - - 151 Share based payments 121 563 33 Exercise of warrants 607 - 1,211 Issued as at December 31 16,009 11,222 7,662 D. Financing rounds 1. In June 2018, in a registered direct offering on the NASDAQ, the Company raised a gross amount of USD 8.1 million (approximately USD 7.4 million net of placement agent fees and other offering related expenses). In this registered direct offering, the Company issued 3,260,000 ADSs and, in a concurrent private placement, 1,630,000 non-listed warrants to purchase 1,630,000 ADSs. Each non-listed warrant is exercisable until December 5, 2023 at an exercise price of USD 2.80 per ADS. The warrant holders have the option to exercise cashless, and the warrants were therefore accounted for as a derivative liability. The ADS’s issued were recorded in equity in an amount of USD 4,276 thousand, net of issuance expenses. The warrants were recorded as a liability in the amount of USD 3,467 thousand. Issuance expenses related to the warrants, in the amount of USD 301 thousand were recorded to finance expenses. This derivative instrument is classified as a Level 3 financial instrument, See Note 20B. 2. In July 2017, in a registered direct offering on the NASDAQ, the Company raised a gross amount of USD 3.5 million (approximately USD 3.1 million net of placement agent fees and other offering related expenses). In this registered direct offering, the Company issued 2,431,746 ADSs in a concurrent private placement and 1,215,873 non-listed warrants to purchase 1,215,873 ADSs. Each non-listed warrant is exercisable until January 14, 2023 at an exercise price of USD 1.50 per ADS. The ADS’s issued were recorded in equity and in an amount of USD 2,174 thousand. The warrants were considered a derivative instrument (due to a cashless exercise feature) and were recorded as a liability. During August 2018 the warrants were listed for trading, and subsequently the cashless feature was expired. Therefore the Company evaluated the derivative instrument on the listing date, recorded financial income and subsequently derecognized the derivative instrument and booked the balance in an amount of USD 567 thousand in equity. See also Note 20B. 3. In July 2016, in a public offering on the NASDAQ, the Company raised a gross amount of USD 12 million (approximately USD 10.0 million net of placement agent fees and other offering related expenses). In the public offering the Company issued securities as follows: (i) 2,378,823 Class A units - comprised of 2,378,823 ADSs and 2,378,823 Series A warrants to purchase 2,378,823 ADSs, and (ii) 1,150,589 Class B units - comprised of 1,150,589 preferred Series B warrants to purchase 1,150,589 ADSs and 1,150,589 Series A warrants to purchase 1,150,589 ADSs. The July 2016 public offering was completed at a price of USD 3.40 per unit. Each Series A warrant is exercisable through November 25, 2020 for an exercise price of USD 3.78, as adjusted following the July 2016 offering. All of the Series B warrants had been exercised by August 31, 2016 for an exercise price of USD 0.01 per ADS. In addition, the Company granted representatives of the placement agent non-traded warrants to purchase up to 141,176 ADSs for an exercise price of USD 4.08. E. Other equity transactions 1. During the reported year 343 thousand warrants, issued in July 2017, were exercised into 343 thousand shares for a consideration of USD 515 thousand. In addition, 484 thousand warrants, issued in July 2017, were exercised into 264 thousand shares on a cashless exercise, and an amount of USD 1,618 thousand was recorded to share premium against derivative liabilities. 2. During 2018 the Company issued 121 thousand ordinary shares on account of vested RSUs granted in 2017. See also Note 10. 3. On October 30, 2017, the Company issued to a vendor of the Company, in consideration for services provided by the vendor to the Company, 67,367 ADSs. The fair value of the services provided was measured at USD 150 thousand, out of which, USD 96 were recorded as share premium against general and administrative expenses in 2017 and USD 54 thousand were recorded as share premium against general and administrative expenses in 2018. 4. During October and December 2017, the Company issued 496,533 ordinary shares on account of vested RSUs. See also Note 10. 5. During 2016, the Company issued 33,455 shares to service providers for services granted. The fair value of the shares was measured at the fair value of the services, and amounted to USD 103 thousand. 6. In May 2016 the Company issued 150,494 shares to Dexcel Ltd. following meeting a milestone in accordance with the agreement between the Company and Dexcel Ltd. The fair value of the shares was USD 500 thousand. 7. During 2016, the Company issued 1,211,306 shares derived from the exercise of Series A warrants, for proceeds of USD 302 thousand. F. Non-controlling interests The following table summarizes the information relating to a subsidiary that has non-controlling interests, before any intra-group eliminations: December 31, December 31, TyrNovo Ltd. in USD thousand Non-controlling interests percentage 2.4 % 35.28 % Non-current assets 9 3 Current assets 415 158 Current liabilities (4,120 ) (2,676 ) Net assets (3,696 ) (2,515 ) Net assets attributable to non-controlling interests (89 ) (887 ) Loss for the year 3,688 2,088 Loss allocated to non-controlling interests 369 736

Share-based Payment Arrangement

Share-based Payment Arrangements	12 Months Ended
	Dec. 31, 2018
Share-based Payment Arrangements [Abstract]
Share-based Payment Arrangements	Note 10 - Share-based Payment Arrangements A. On November 20, 2018, the Company granted 159,759 options and 59,720 RSUs to two executives. The RSUs and options have a vesting period of 3 years from the commencement of the offeree’s engagement with the Group, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 5 years from the date of the grant. The options shall have an exercise price equals to USD 1.59 per one ordinary share. 34,825 thousand RSUs were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 71 thousand and USD 127 thousand, respectively. On August 15, 2017, the Company’s Board of Directors approved grants of 17 thousand RSUs and 29 thousand options to two consultants. The RSUs and/or options have a vesting period of 3 years from the commencement of the service provider’s engagement, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. The options shall have an exercise price equals to USD 1.84 per one ordinary share. 29 thousand options and 9 thousand RSUs were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 32 thousand and USD 31 thousand, respectively. In addition, on August 15, 2017, the Company’s Board of Directors granted of 42 thousand RSUs and 16 thousand options to one consultant . The RSUs have a vesting period of 3 years from November 25, 2015, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. The options shall have an exercise price equal to USD 4.39 per one ordinary share and shall have a vesting period of 3 years from May 22, 2016. The exercise period is 7 years from the date of the grant. 8 thousand options and 28 thousand RSUs were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 76 thousand and USD 15 thousand, respectively. In June 2017, the Company’s board of directors decided to amend the Company’s 2016 Equity-Based Incentive Plan (the “Plan”) to increase the number of Ordinary Shares available for issuance thereunder by an additional 1,900,000 Ordinary Shares. No other amendments were made to the Plan. On August 1, 2017, the Company’s board of directors approved grants of 608 thousand RSUs and 440 thousand options. The options have an exercise price equals to USD1.85 per one ordinary share. The RSUs and/or options have a vesting period of 3 years from the commencement of the Officer’s or Director’s engagement, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. 22 thousand RSUs and 20 thousand options were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 1,326 thousand and USD 592 thousand, respectively. In June 2016, the Company’s shareholders granted 123,438 options to the chairman of the board of directors In May 2016 and June 2016, the Company granted 364,069 options to the chairman of board of directors, chief executive officer, chief financial officer, senior employees and a service provider. Each option may be exercised into one ordinary share, at an exercise price of USD 4.04 –USD 4.07 per share over a vesting period of 3 years. The exercise period is 8 years from date of issuance provided, however that with respect to 297,874 thousand of the options granted to directors of the Company, no options were exercisable prior to the Company’s adoption of a revised compensation policy in accordance with the Companies Law. In July 2017 a revised compensation policy was adopted. The Company recorded an expense of USD 719 thousand USD (2017 - 2,196 thousand), of which USD 660 thousand (2017 - USD 1,905 thousand) are to key management personnel. B Other share based payment arrangements See Note 9E with regards to share based payments to service providers. C. The number and weighted average exercise prices (in USD (*)) of share options are as follows: Weighted average exercise price Number of options 2018 2017 2016 2018 2017 2016 Outstanding on January 1 3.08 4.29 4.86 1,002,021 519,746 175,536 Expired during the year 7.00 20.72 4.16 30,000 2,239 143,297 Granted during the year 1.59 1.85 4.05 159,759 484,515 487,507 Outstanding on December 31 2.60 3.08 4.29 1,131,780 1,002,022 519,746 Exercisable on December 31 2.95 2.83 3.31 873,344 708,879 113,490 (*) The exercise price is denominated in NIS and are re-measured using historic exchange rates. The options outstanding at December 31, 2018 had an exercise price of USD 1.59- USD 4.39 (2017 -USD 1.84 – USD 7.01, 2016 - USD 4.04 - USD 4.07), and weighted D. The number of RSUs are as follows: Number of RSUs 2018 2017 Outstanding at January 1 170,727 - Granted during the year 59,720 667,260 Vested during the year 121,028 496,534 Outstanding at December 31 109,419 170,726 E. Options to service providers were measured at the fair value of the service, when available. The fair value of the Company’s share options granted to employees, directors and service providers, where fair value of service was not measurable, was measured using the binominal model, using the fair value of the traded warrants with similar terms, making some adjustments to reflect the specific terms of the options based on the expected duration. The following assumptions were used : 2018 2017 2016 Share Price - USD 1.18 1.82 - 2.17 1.06 - 1.348 Option price - USD 0.80 3.28 - 3.82 21.38 - 28.40 Expected volatility (%) 105.77 80.65 - 80.91 - Expected duration (years) 4.95 6.77 - 6.97 4-8 Dividend yield (%) - - - Risk free rate interest rate (%) 1.41 % 1.36 - 1.39 N/A F. On January 3, 2018, TyrNovo granted 1,170 options of TyrNovo to certain employees. The options were fully vested at the date of grant. The exercise period is 7 years from the date of the grant. The options shall have an exercise price equals to USD 0.29 per one ordinary share. The fair value of these options at the date of the grant was measured at USD 431 thousand. The fair value of these options was measured using the binominal model, The following assumptions were used : 2018 Share Price - USD 368.39 Option price - USD 369.39 Expected volatility (%) 79.16 Expected duration (years) 7 Dividend yield (%) - Risk free rate interest rate (%) 2.4 % In 2018, the Company recorded a share-based compensation expense of USD 431 thousand USD, of which USD 402 thousand are to key management personnel. G. Expenses recognized in the financial statements: For the year ended December 31 2018 2017 2016 USD thousands Research and development expenses 546 709 176 General and administrative expenses 227 1,570 224 Other expenses - 29 - Total share-based expense recognized 773 2,308 400

Transactions and Balances with

Transactions and Balances with Related Parties	12 Months Ended
	Dec. 31, 2018
Transactions and Balances with Related Parties [Abstract]
Transactions and Balances with Related Parties	Note 11 - Transactions and Balances with Related Parties In addition to their salaries or fees, the Group also provides non-cash benefits to directors and executive officers, and contributes to a post-employment defined contribution plan on behalf of employees. Certain executive officers are entitled to termination benefits of up to 6 monthly salaries or fees. Executive officers also participate in the Group’s share option programs. For further information, see Note 10 regarding share-based payments. Expenses of key management personnel: The Company recorded expenses to executive officers: For the year ended December 31 2018 2017 2016 USD thousands Short - term employee benefits 2,165 2,305 1,282 Post-employment benefits 16 137 25 Share based payments 574 1,669 244 2,755 4,111 1,551 The Company recorded expenses to directors: For the year ended December 31 2018 2017 2016 USD thousands Short - term benefits 268 217 54 Share based payments 86 236 - 354 453 54

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2018
Commitments and Contingent Liabilities [Abstract]
Commitments and contingent liabilities	Note 12 – Commitments and contingent liabilities A. Commitments 1. At the end of the reporting period, the future minimum lease payments under non-cancellable operating leases are as follows: 2018 2017 USD thousands USD thousands Less than one year 195 202 Between one to five years 751 784 More than five years 360 584 The Company has a bank guarantee for the Group’s leases in an amount of USD 46 thousand and USD 50 thousand as of December 31, 2018 and December 31, 2017, respectively. 2. Certain of the Company’s senior executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain milestones, including fund raising, merger transactions, and agreements for the commercialization of the Company’s products. These financial statements include bonuses in the amount of USD 777 thousand for the year ended December 31, 2018, and USD 1,056 thousand for the year ended December 31, 2017. 3. Certain of the Company’s senior executives are entitled to termination benefits under the terms of their employment and consulting agreements. These benefits are measured based on the time of service and their monthly pay and the expected term of their employment. These financial statements include a liability due to these grants of USD 405 thousand and USD 492 thousand, as of December 31, 2018 and 2017, respectively. 4. Kitov Pharma’s subsidiary, TyrNovo, has obligations to the Israel Innovation Authority (hereinafter: “IIA”) with respect to grants it received from the IIA in connection with TyrNovo’s technology. The requirements and restrictions for such grants are found in the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984 and the IIA’s rules and guidelines and the terms of these grants. In general, a recipient company is obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of, a research and development program funded by the IIA (currently a yearly rate of 3% to 6%), up to the aggregate amount of the total grants received by the IIA, plus annual interest. TyrNovo’s technologies were developed, at least in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its IIA funded products and related services. As of December 31, 2018, the maximum royalty amount that would be payable by TyrNovo, excluding interest, is approximately NIS 5.5 million (USD 1.5 million), and as of such date, TyrNovo had not paid any royalties to the IIA. The financial statements do not include a liability for royalties for these grants as the fair value of the liability in accordance with IAS 20 was estimated to be 0. 5. TyrNovo has entered into a license agreement (the “License Agreement”) with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (hereafter “Yissum”) dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer to sell, or sell products, that are derived from Yissum’s licensed technology. In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement. B. Claims 1. In December 2015, a lawsuit and a motion to approve such lawsuit as a class action was filed against the Company and its directors by shareholders who were holding the Company’s Tel Aviv Stock Exchange listed securities before the offering that took place in November 2015, claiming damages for the purported class in the motion totaling NIS 16.4 million (USD 4.3 million) due to the said offering (the “Motion”). The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion. Additional preliminary hearings were held during 2017. On October 24, 2017 the court issued a ruling to stay proceedings in this matter until January 15, 2018 due to the ongoing ISA Investigation (See Note 12b(3) below). At the request of the ISA, this stay was subsequently extended several times by the court, which ruled that the evidentiary hearing shall not be rescheduled and that the stay of proceedings shall remain in place pending delivery of a notice to the court by the ISA by no later than April 11, 2019 with respect to an update on the ISA Investigation. 2. On November 8, 2016, a shareholder of the Company submitted a request to the court in connection with the Motion to be excluded from the purported class and claiming to have independent causes of action and claims of approximately NIS 1 million (USD 262 Thousand) (the “Petition to Exclude”). The Company responded to the court as required, and, amongst other arguments, the Company noted that such shareholder cannot petition to be excluded from the purported class. The court ordered the shareholder to respond and he has done so. In May 2018 the shareholder submitted an independent lawsuit against the Company in the Haifa Magistrates Court seeking damages of approximately NIS 1.1 million (USD 306 Thousand) (the “Separate Lawsuit”). In August 2018 the Haifa Magistrates Court transferred the Separate Lawsuit to the Tel Aviv Magistrates Court. The Company is of the view that such shareholder’s claims are identical to the asserted claims for damages in the Motion, and has notified the court of such and have sought a stay of proceedings pending the outcome of the Motion. A hearing on the Company’s motion to dismiss the Separate Lawsuit and/or stay the proceedings has been scheduled for May 1, 2019. The Company’s management rejects the claims asserted in the Motion as well as in the Petition to Exclude and the Separate Lawsuit, and, in consultation with its legal advisors, believes that the likelihood of the Company not incurring any financial obligation as a result of this class action exceeds the likelihood that the Company will incur a financial obligation. Therefore, no provision for this matter was recorded in these financial statements. 3. In February 2017 the Company announced that the Israeli Securities Authority has begun a formal investigation into, amongst other matters, the Company’s public disclosures in connection with the Data Monitoring Committee (DMC) appointed in connection with the Company’s Phase III trial of KIT-302, the results of which were announced in December 2015, and what information regarding the DMC was disclosed publicly by Kitov. A DMC is generally an external independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing, and, in the case of the KIT-302 Phase III clinical trial, was established in order to analyze the preliminary results of the initial patient group enrolled in the clinical trial and determine the number of additional patients, if any, that Kitov might have needed to recruit in order to demonstrate statistical validity, and to meet the primary end point of the clinical trial. In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a “Motion”), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), and served on the Company, with each Motion relating to the above noted formal investigation by the Israeli Securities Authority (ISA) into the Company’s public disclosures (the 2017 Motions”). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other 2 of the 2017 Motions (“Petition for Dismissal”). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion was filed against the Company, the Company’s executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition, an aggregate loss of approximately NIS 29 million (approximately USD 8 million). The Company and other defendants have not yet delivered their response to the court, and will do so in accordance with applicable law and the court’s instructions. The court has ordered a stay of proceedings due to the ongoing ISA Investigation until mid-April 2019. Under applicable Israeli law, a motion to approve a lawsuit as a class action initially needs to be approved as such by the court. Only after such approval is granted by the court, will the court proceed to the second stage of hearing the underlying claims of the class action lawsuit. The Company’s management rejects the claims in all of the aforesaid Motions and class action lawsuits. At this preliminary stage the Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the Motions’ and/or lawsuits in the U.S.A. and in Israel as to the probability of success or the scope of potential exposure, if any. Therefore, no provision for this matter was recorded in these financial statements. On February 7, 2017, a holder of the Company’s securities listed on the NASDAQ filed in the United States District Court (Southern District of New York), a federal securities class action relating to the above noted formal investigation by the ISA into the Company’s public disclosures against the Company, its CEO and CFO, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company’s securities in the Company’s initial public offering in the USA on November 20, 2015, as well as in open market purchases, as a result of the Company allegedly including misleading information in its public filings. An amended complaint was filed on June 19, 2017, which complaint limited the scope of its claims as compared to the original complaint. On August 2, 2017, the Company filed a motion to dismiss the amended complaint in its entirety. In addition, on September 20, 2017, the Company filed a letter motion requesting a conference on the issue of whether this litigation should be dismissed. On September 21 st th On February 10, 2017, a holder of the Company’s securities listed on the NASDAQ filed in the Superior Court of the State of California, a securities class action relating to the above noted formal investigation by the ISA into the Company’s public disclosures, against the Company, its CEO and CFO and the underwriters in the Company’s initial public offering in the USA on November 20, 2015, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company’s securities in such public offering as a result of the Company allegedly including misleading information in its public filings. On March 20, 2017, a holder the Company’s securities listed on the NASDAQ filed in the Superior Court of the State of California, a securities class action against the Company, its CEO and CFO and the underwriters in the Company’s initial public offering in the USA on November 20, 2015, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company’s securities in such public offering as a result of the Company allegedly including misleading information in its public filings. On April 6, 2017, the Superior Court of the State of California for the County of San Mateo entered an order consolidating the two California putative class actions. An amended complaint was filed on or about June 5, 2017. On December 15, 2017, the Company filed a motion to stay discovery pending the resolution of the ISA Investigation. Following Plaintiffs’ opposition to the Company’s motion on January 5, 2018 and the Company’s reply in further support on January 16, 2018, the court ruled in the Company’s favor after arguments on January 29th, 2018 staying discovery by Plaintiffs against the Company and the individual defendants until June 1, 2018, at which point the parties are to update the court on the status of the ISA’s investigation. Discovery against the underwriters continued. In June 2018 the Company entered into a Memorandum of Understanding and subsequently, in July 2018 entered into a Stipulation of Settlement with respect to the shareholder class action lawsuits pending against it. Under the terms of the proposed settlement, the purported classes in all of the actions will receive aggregate consideration of USD 2.0 million. The settlement consideration, as well as ancillary expenses, will be funded by the Company’s insurance carriers, who have indicated to the Company that they have already made reserves for the settlement consideration. The settlement was approved by the court in March 2019. Pursuant to the final settlement, the Company and its directors and officers are released from the claims that were asserted or could have been asserted in the Actions by class members participating in the settlement. The final approved settlement is subject to the completion of final documentation, funding of the USD 2.0 million in cash by the Company’s insurance carriers, and other customary closing conditions.

Revenues

Revenues	12 Months Ended
	Dec. 31, 2018
Revenues [Abstract]
Revenues	Note 13 - Revenues Revenues in 2018 and 2017 are derived from milestone payments for a right to use agreements in the far-east.

Research and Development Expens

Research and Development Expenses	12 Months Ended
	Dec. 31, 2018
Research and Development Expenses [Abstract]
Research and Development Expenses	Note 14 - Research and Development Expenses For the year ended December 31 2018 2017 2016 USD thousands Salaries, wages and related expenses 933 969 493 Share-based payments (see also Note 10) 546 709 176 Service providers 3,789 2,962 3,511 5,268 4,640 4,180

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2018
General and Administrative Expenses [Abstract]
General and Administrative Expenses	Note 15 - General and Administrative Expenses A. For the year ended December 31 2018 2017 2016 USD thousands Employees and officers compensation 1,733 1,984 1,131 Share-based payments (see also Note 10) 87 1,224 121 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 12B) 690 893 84 Other professional consulting 1,525 1,306 1,059 Board member remuneration and insurance 556 552 155 Rent and office maintenance 243 196 94 Travel 143 131 99 Car expenses 85 64 42 Depreciation 7 4 2 Other 126 (*)43 216 5,195 6,397 3,003 (*) Restated due to full retrospective method of adoption of IFRS 15 , Revenue from Contracts with Customers, B. The Consolidated Statements of Operations for the year ended December 31, 2018, include refunds from the insurance company in respect of legal expenses in the amount of USD 743 thousand.

Other Expenses (Income)

Other Expenses (Income)	12 Months Ended
	Dec. 31, 2018
Other Expenses (Income) [Abstract]
Other Expenses (Income)	Note 16 - Other Expenses (Income) During 2017 the Company recorded an amount of USD 1,029 thousand in its financial statements under Other Expenses, with regards to rights granted to Taoz as part of the Company’s settlement with Taoz, regarding the acquisition of TyrNovo, See also Note 5B. During 2018, the Company acquired Taoz’s holdings in TyrNovo. As part of the agreement with Taoz, it waived the rights described in Note 5B, and the Company recorded an amount of USD 894 thousand under Other Income, see also Note 5D .

Finance Expense (Income)

Finance Expense (Income)	12 Months Ended
	Dec. 31, 2018
Finance Expense (Income) [Abstract]
Finance Expense (Income)	Note 17 - Finance Expense (Income) For the year ended December 31 2018 2017 2016 USD thousands Net change in fair value of derivatives Expenses - 1,049 5,160 Income (2,740 ) - (141 ) Net change in fair value of derivatives (*) (2,740 ) 1,049 5,019 (*) The derivatives are related to the fair value adjustments of warrants. Warrants issued in 2016 and 2017 included an anti-dilution provision whereby the exercise price of the warrants were subject to “weighted average” ratchet anti-dilution provision, so that upon future issuance of the Company’s ADSs, subject to specified exceptions, at a price less than the exercise price then in effect, the exercise price will be reduced. The ratchet for the 2017 warrants expired on January 14, 2018, and the ratchet for the 2016 Series A warrants expired on November 25, 2016. The 2017 warrants included a cashless exercise feature, which expired on August 8, 2018 when the Company filed a registration statement with the SEC, registering the shares that will derive from future exercise of these warrants. The 2018 warrants include a cashless exercise feature (See Note 20B). For the year ended December 31 2018 2017 2016 USD thousands Finance expense Fees and interest expense 9 26 6 Loss from exchange rate differences, net 106 - 55 Payment to Taoz, see Note 5D 160 - - Warrant issuance costs 301 - - 576 26 61 For the year ended December 31 2018 2017 2016 USD thousands Finance income Income from exchange rate differences, net - (22 ) - Interest income from short term deposits (93 ) (106 ) (138 ) (93 ) (128 ) (138 )

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2018
Taxes on Income [Abstract]
Taxes on Income	Note 18 - Taxes on Income A. Corporate tax rate The tax rate applicable to the Group for 2018 is 23%. The tax rate in 2017 was 24%. B. The Company and its subsidiaries incurred losses in 2017, as well as carry-forward losses from previous years, which are not expected to be utilized in the foreseeable future. Therefore, the Group did not record current taxes or deferred taxes. The carry-forward loss for tax purposes for the Company and its subsidiaries, and the unrecognized research and development expenses, amounts to USD 33.1 million as of December 31, 2018 (2017 – USD 28.2 million, 2016 – USD 13.2 million). C. The Company’s tax assessments are deemed finalized through the end of 2013, pursuant to section 145 of the Israeli Income Tax Ordinance. The subsidiary’s tax assessments are deemed finalized through the end of 2014, pursuant to section 145 of the Israeli Income Tax Ordinance. Currently the tax years of 2014 - 2016 for Kitov Pharma Ltd. are being assessed by the Israeli Tax Authority.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2018
Employee Benefits [Abstract]
Employee benefits	Note 19 - Employee benefits A. Employee benefits include post-employment benefits and short term benefits. Post-employment benefits are part of key management compensation – see Note 11 on related parties. Balances include: Year ended December 31 2018 2017 USD thousands USD thousands Short-term benefits 136 112 Post-employment benefits 405 492 B. Post-employment benefit plans – defined contribution plan The Company has a defined contribution plan in respect of the Company’s liability in respect of its employees who are subject to Section 14 of the Severance Pay Law – 1963. Year ended December 31 2018 2017 2016 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 95 52 39

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2018
Financial Instruments [Abstract]
Financial Instruments	Note 20 – Financial Instruments Framework for risk management The Board of Directors has overall responsibility for the establishment and oversight of the Group’s risk management framework. The Group’s risk management practice was formulated to identify and analyze the risks that the Group faces, to set appropriate limits for the risks and controls, and to monitor the risks and their compliance with the limits. The risk policy and risk management methods are reviewed regularly to reflect changes in market conditions and in the Group’s operations. The Group acts to develop an effective control environment in which all employees understand their roles and commitment. A. Risk management 1. Credit risk Credit risk is the risk of financial loss to the Group if a debtor or counterparty to a financial instrument fails to meet its contractual obligations, and arises mainly from the Company’s receivables. The Group restricts exposure to credit risk by investing only in bank deposits. Exposure to credit risk The Group held cash and cash equivalents and short-term deposits of USD 6,684 thousand at December 31, 2018 (2017 – USD 7,435). These are held with banks, which are rated A2, based on Moody’s Rating Agency ratings. The short-term deposits, mainly in USD, bear fixed interest ranging between 0.02% - 2.87%. The carrying amount of cash and cash equivalents and short-term deposits approximate their fair value. 2. Market risk Market risk is the risk that changes in market prices, such as foreign currency exchange rates, the CPI, interest rates and the prices of equity instruments, will influence the Group’s results or the value of its holdings in financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing returns. Currency risk The Group is exposed to currency risk mainly for cash and purchases for research and development expenses that are denominated in dollars and euros. Therefore, the Group is exposed to exchange rate fluctuations in these currencies against the NIS and takes steps to reduce the currency risk by maintaining its liquid resources in accordance with its future needs. Set forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2018: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 15 38 754 (38 ) (15 ) Other current assets 3 7 135 (7 ) (3 ) Accounts payable (6 ) (16 ) (312) 16 6 Other payables (29 ) (71 ) (1,425) 71 29 Post-employment benefit liabilities (5 ) (12 ) (235) 12 5 Total income (loss) (22 ) (54 ) 54 22 B. Fair value hierarchy of financial instruments measured at fair value: December 31, 2018 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9D(1)) - - 554 554 December 31, 2017 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9D(2)) - - 2,012 2,012 Put option to Taoz (see Note 5B) - - 1,030 1,030 - - 3,042 3,042 Details regarding fair value measurement at Level 3: Financial instrument Valuation method for determining fair value Significant unobservable inputs As of December 31, 2018 Warrants Black - Scholes expected term 4.9 years expected volatility 97.29 % annual risk free interest 2.51 % dividend yield 0 % As of December 31, 2017 Warrants Black - Scholes expected term 5.5 years expected volatility 81.66 % annual risk free interest 1.94 % dividend yield 0 % Investment and Put option to Taoz Monte–Carlo Simulation Valuation at milestone (USD thousand) 12,000 – 17,000 Share Price (USD) 812 – 1,150 Probability of reaching milestone (%) 50 % Risk free interest rate (%) 1.71% - 1.97% expected volatility 74.96 %

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 21 - Subsequent Events A. In January 2019, in a registered direct offering on the NASDAQ, the Company raised gross amount of USD 6.0 million (approximately USD 5.4 million net of placement agent fees and other offering related expenses). In this registered direct offering, the Company issued 3,428,572 ADSs and, in a concurrent private placement, 2,571,430 non-listed warrants to purchase 2,571,430 ADSs. Each non-listed warrant is exercisable until July 18, 2024 at an exercise price of USD 2.00 per ADS. The warrant holders have the option to exercise cashless. B. On January 2, 2019 the Company executed an agreement with Coeptis Pharmaceuticals Inc. (“Coeptis”) for the marketing and distribution of Consensi TM C. On March 14, 2019 the Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM-24, (“FameWave) from its shareholders in exchange for $10 million worth of its newly issued ADSs with a long term lock-up period, priced at $1.23 per ADS, plus 50% warrant coverage based on an exercise price of $1.98 per ADS with a 4-year term. In addition, the Company will provide a loan to FameWave of up to approximately $2 million to be paid to cCAM BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and Dohme Corp., known as “MSD” in Israel, which discovered CM-24, or to repay certain loans provided by FameWave’s shareholders. The transaction has been approved by the boards of the Company and FameWave and is expected to close during the third quarter of 2019 subject to: approval of the Company shareholders; closing of the transaction for the return of CM-24 to FameWave by MSD; finalization by FameWave of the joint clinical collaboration agreement; and satisfaction of other customary closing conditions. Should the complete transaction not close, the Company will be entitled to repayment of the amounts loaned by the Company out of amounts actually received by FameWave from commercialization transactions of CM-24. If no such commercialization transaction is consummated within 36 months from termination, Company will be entitled to 20% of FameWave in return for the approximately $2 million loan which was previously provided. Furthermore, should the transaction not close due to the failure of FameWave to finalize the clinical collaboration agreement, or the failure of certain other closing conditions to be fulfilled by the current shareholders of FameWave, then the Company will be entitled to 100% of FameWave in return for the approximately $2 million loan which was previously provided D. During March 2019, the board of directors of the Company approved the grant of 3,132,895 options to directors, employees and consultants, exercisable to 3,132,895 ordinary shares with no par value of the Company, out of which 2,086,529 options to be granted to directors are subject to shareholders’ approval.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Basis of consolidation	A. Basis of consolidation 1. Business combination The Group accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. 4. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements.
Foreign currency transactions	B. Foreign currency transactions Transactions in foreign currency are translated to the functional currency of the Group at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currency as of the reporting date are translated into the functional currency at the exchange rate as of the said date. Exchange rate differences with respect to monetary items are the differences between the amortized cost in the functional currency as of the start of the year, adjusted for the effective interest during the year, and the amortized cost in foreign currency, translated at the exchange rate as of the end of the year. Non-monetary items denominated in foreign currency and measured at historical cost, are translated using the exchange rate as of the transaction date. Exchange rate differences arising from translation into the functional currency are recognized on the statement of operations as financial expenses.
Financial instruments	C. Financial instruments 1. Non-Derivative financial instruments a. Non-derivative financial assets – policy applicable as from January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: assets at amortized cost; assets at fair value through other comprehensive income – investments in debt instruments; assets at fair value through other comprehensive income – investments in equity instruments; or assets at fair value through profit or loss. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. b. Non-derivative financial assets – policy applicable before January 1, 2018 Initial recognition and measurement of financial assets The Group initially recognizes receivables and deposits on the date that they are created. All other financial assets acquired in a regular way purchase, are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument, meaning on the date the Group undertook to purchase or sell the asset. Non-derivative financial assets include: cash and cash equivalents, short term deposits and other receivables. Cash and cash equivalents include cash balances available for immediate use and call deposits. Cash equivalents include short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. c. Non-derivative financial liabilities Non-derivative financial liabilities include: accounts payables and other accounts payable. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. d. Derivative financial liabilities The Group holds derivative financial instruments that do not serve for hedging purposes. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation, and classified as level 3.
Intangible assets	D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve also plans or designs for the production of new or substantially improved products and processes. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life. 4. Timing of impairment testing Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains goodwill, or intangible assets that have indefinite useful lives or are unavailable for use.
Loss per share	E. Loss per share The Group presents loss per share data for its ordinary share capital. Loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period.
Employee benefits	F. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance companies or with funds managed by a trustee, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Other long-term employee benefits The Group’s net obligation in respect of long-term employee benefits plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.
Share-based payment transactions	G. Share-based payment transactions The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.
Provisions	H. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.
Revenue	I. Revenue The Group recognizes revenue from upfront and milestone payments at the point in time the milestone criteria is highly probable to be met and collectability is probable The Group will recognize sales based on royalty income, earned through a license, when the underlying sales will occur. Identifying the contract The Group accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Group can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Group can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Group is entitled to in exchange for the goods or services transferred to the customer, will be collected. For the purpose of section (e) the Group examines, inter alia, the percentage of the advance payments received and the spread of the contractual payments, past experience with the customer and the status and existence of sufficient collateral. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Group has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. Identifying performance obligations On the contract’s inception date the Group assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer one of the following: (a) Goods or services (or a bundle of goods or services) that are distinct; or (b) A series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. The Group identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Group’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. In order to examine whether a promise to transfer goods or services is separately identifiable, the Group examines whether it is providing a significant service of integrating the goods or services with other goods or services promised in the contract into one integrated outcome that is the purpose of the contract. Determining the transaction price The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for the license and commercialization agreement. The Group takes into account the effects of all the following elements when determining the transaction price: variable consideration, the existence of a significant financing component, non-cash consideration, and consideration payable to the customer. Variable consideration The Group includes variable consideration, or part of it, in the transaction price only when it is highly probable that its inclusion will not result in a significant revenue reversal in the future when the uncertainty has been subsequently resolved. At the end of each reporting period and if necessary, the Group revises the amount of the variable consideration included in the transaction price. Right to use and right to access To determine whether the Group’s promise to grant a license provides a customer with either a right to access the Group’s IP or a right-to-use the Group’s IP, the Group considers whether a customer can direct the use of, and obtain substantially all of the remaining benefits from, a license at the point in time at which the license is granted. A license is considered a “right-to-use” license when the customer maintains control of the IP upon its transfer. However, if the grantor of the license maintains involvement with the IP after its transfer, and the customer cannot direct the use of, and obtain substantially all of the remaining benefits from the license, then the license is considered a right-to-access license.
Financing income and expense	J. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, and income from short term deposits. Finance expenses include loss from exchange rate differences. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received and interest paid are presented as part of cash flows from financing activities.
Equity	K. Equity Incremental costs directly attributable to an expected issuance of an instrument that will be classified as equity are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from the equity upon the initial recognition of the equity instruments, or are expensed as financing expenses in the statement of operations when the issuance is no longer expected to take place.
Issuance of units of securities	L. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above.
Deferred tax	M. Deferred tax A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable profits will be available against which they can be utilized.
New standards and interpretations not yet adopted	N. New standards and interpretations not yet adopted (1) IFRS 16, Leases The standard replaces IAS 17, Leases In addition, IFRS 16 permits the lessee to apply the definition of the term lease according to one of the following two alternatives consistently for all leases: retrospective application for all the lease agreements, which means reassessing the existence of a lease for each separate contract, or alternatively to apply a practical expedient that permits continuing with the assessment made regarding existence of a lease based on the guidance in IAS 17, Leases Determining whether an Arrangement contains a Lease IFRS 16 is applicable for annual periods as of January 1, 2019. IFRS 16 includes various alternative transitional provisions, so that companies can choose between one of the following alternatives at initial application consistently for all leases: full retrospective application or recognizing a cumulative effect, which means application (with the possibility of certain practical expedients) as from the mandatory effective date with an adjustment to the balance of retained earnings at that date. Method of application and expected effects The Group adopted IFRS 16 as from January 1, 2019 using the cumulative effect method as at January 1, 2019. Expedients: (1) Not applying the requirement to recognize a right-of-use asset and a lease liability in respect of short-term leases of up to one year. (2) Not separating non-lease components from lease components and instead accounting for all the lease components and related non-lease components as a single lease component. (3) Not applying the requirement to recognize a right-of-use asset and a lease liability in respect of leases where the underlying asset has a low value. (4) Applying a single discount rate to a portfolio of leases with reasonably similar characteristics. Expected effects: The Group plans to elect to apply the transitional provision of recognizing a lease liability at the date of initial application, for all the leases that award it control over the use of identified assets for a specified period of time, and except for when the Group has elected to apply the standard’s expedients as aforesaid, according to the present value of the future lease payments discounted at the incremental borrowing rate of the lessee at that date, and concurrently recognizing a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments that were recognized as an asset or liability before the date of initial application. Therefore, application of the standard is not expected to have an effect on the balance of retained earnings at the date of initial application. These changes are expected to result in an increase of USD 1.2 million in the balance of right-of-use assets at the date of initial application and an increase of USD 1.2 million in the balance of the lease liability at the date of initial application. Accordingly, depreciation and amortization expenses will be recognized in subsequent periods in respect of the right-of-use asset, and the need for recognizing impairment of the right-of-use asset will be examined in accordance with IAS 36. Furthermore, financing expenses will be recognized in respect of the lease liability. Therefore, as from the date of initial application and in subsequent periods, depreciation expenses and financing expenses will be recognized instead of lease expenses relating to assets leased under an operating lease, which were presented as part of the general and administrative expenses item in the income statement. In addition, the nominal discount rate used for measuring the lease liability is 8%.

Basis of Preparation of the F_2

Basis of Preparation of the Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2018
Basis of Preparation of the Financial Statements [Abstract]
Schedule of changes in exchange rates	Representative exchange rate of USD (NIS/USD 1) Date of financial statements: December 31, 2018 3.748 December 31, 2017 3.467 December 31, 2016 3.845 Changes in exchange rates for the year ended: % December 31, 2018 8.1 December 31, 2017 (9.8 ) December 31, 2016 (1.5 )
Schedule of expected effect of the standard's application on the relevant items of the statement of financial position	According to the previous According to policy The change IFRS 15 USD thousands USD thousands USD thousands Deferred income 95 (95 ) - Accumulated loss (38,567 ) 95 (38,472 )
Schedule of expected effect of the standard's application on the relevant items of the statement of operations position	According to the previous According to policy The change IFRS 15 USD thousands USD thousands USD thousands Revenues - (100 ) (100 ) General and administrative expenses 6,392 5 6,397 Operating Loss 12,061 (95 ) 11,966 Loss for the year 13,008 (95 ) 12,913 Impact on basic and diluted loss per share data : Basic and diluted loss per share -USD (*) (0.02 ) 1.37 (*) Restated to reflect a 20:1 reverse share split, that took place in January 2019, see Note 9A.

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
	Dec. 31, 2018
Operating Segments [Abstract]
Schedule of segment reporting information by segment	For the year ended December 31, 2018 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 1,000 - 1,000 - 1,000 Research and development expenses 2,185 2,537 4,722 546 5,268 Operating loss 4,730 3,217 7,947 (121 ) 7,826 Finance income, net (2,257 ) Loss for the year 5,569 For the year ended December 31, 2017 Pain and Hypertension Oncology Total reportable segments Reconciliations (*) Total consolidated USD in thousands Revenues 100 - 100 - 100 Research and development expenses 2,603 1,328 3,931 709 4,640 Operating loss 6,674 1,951 8,625 3,341 11,966 Finance expenses, net 947 Loss for the year 12,913 (*) Includes employees share based expenses and other expenses/income related to rights granted to Taoz.

Subsidiary (Tables)

Subsidiary (Tables)	12 Months Ended
	Dec. 31, 2018
Subsidiary [Abstract]
Summary of acquisition date fair value of each major class of consideration	USD thousands Cash 2,000 Equity instruments issued (564,625 Ordinary Shares) (1) 1,800 Assignment of loan to the Company (101 ) Total consideration transferred 3,699 (1) The fair value of the Ordinary Shares issued was based on the listed share price of the Group on January 11, 2017 of approximately USD 3.19 per share.
Schedule of recognized amounts of assets acquired and liabilities assumed at the date of acquisition	USD thousands Current assets 21 Fixed assets, net 3 Intangible assets (2) 6,172 Short-term credit from bank (16 ) Trade payables (123 ) Other payables (212 ) Long-term related parties (130 ) Total net identifiable assets 5,715 (2) In-process research and development
Schedule of condensed information regarding TyrNovo	Amounts provided by the Company to the subsidiary Incorporated and Group’s ownership equity Company’s direct ownership of equity Loans Total investment in subsidiary USD thousands TyrNovo Ltd. Israel 97.6 % 97.6 % (2,366 ) 2,055

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents	As of December 31 2018 2017 USD thousands Balance in USD 4,410 3,322 Balance in other currencies 753 625 Total cash and cash equivalents 5,163 3,947

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Other Current Assets [Abstract]
Schedule of other current assets	As of December 31 2018 2017 USD thousands Government authorities 81 171 Reimbursement of legal fees receivable 743 - Prepaid fee to the Food and Drug Administration 930 - Prepaid expenses and other receivables 76 (*)377 Total other current assets 1,830 548 (*) Including an amount of USD 166 thousand, representing deposits entrusted to Israeli court on behalf of related parties pursuant to an indemnification obligation of the Company, in respect of an investigation of the Israeli Security Authority against the Company. See also Note 12B.

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2018
Other Payables [Abstract]
Schedule of other payables	As of December 31 2018 2017 USD thousands Due to related parties – payroll related 910 1,059 Due to GHP (Note 5A) 167 167 Accrued expenses 852 326 Government authorities 65 107 Payroll related payables 61 87 2,055 1,746

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of company's share capital	As of December 31, 2018 As of December 31, 2017 Number of shares in thousands Authorized Issued and paid-in Authorized Issued and paid-in Ordinary shares, no par value 250,000 16,009 250,000 11,222 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 -
Schedule of changes in share capital during the year	For the year ended December 31 2018 2017 2016 Number of shares in thousands Issued as at January 1 11,222 7,662 3,888 Issuance of ADSs (See D below) 3,260 2,432 2,379 Issuance of shares (See Note 5) 799 565 - Share issuance deriving from a development agreement (See E6 below) - - 151 Share based payments 121 563 33 Exercise of warrants 607 - 1,211 Issued as at December 31 16,009 11,222 7,662
Schedule of information relating to subsidiary that has material non-controlling interests	December 31, December 31, TyrNovo Ltd. in USD thousand Non-controlling interests percentage 2.4 % 35.28 % Non-current assets 9 3 Current assets 415 158 Current liabilities (4,120 ) (2,676 ) Net assets (3,696 ) (2,515 ) Net assets attributable to non-controlling interests (89 ) (887 ) Loss for the year 3,688 2,088 Loss allocated to non-controlling interests 369 736

Share-based Payment Arrangeme_2

Share-based Payment Arrangements (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of range of exercise prices of outstanding share options [line items]
Summary of number and weighted average exercise prices (in nis) of share options	Weighted average exercise price Number of options 2018 2017 2016 2018 2017 2016 Outstanding on January 1 3.08 4.29 4.86 1,002,021 519,746 175,536 Expired during the year 7.00 20.72 4.16 30,000 2,239 143,297 Granted during the year 1.59 1.85 4.05 159,759 484,515 487,507 Outstanding on December 31 2.60 3.08 4.29 1,131,780 1,002,022 519,746 Exercisable on December 31 2.95 2.83 3.31 873,344 708,879 113,490 (*) The exercise price is denominated in NIS and are re-measured using historic exchange rates.
Summary of number of RSUs	Number of RSUs 2018 2017 Outstanding at January 1 170,727 - Granted during the year 59,720 667,260 Vested during the year 121,028 496,534 Outstanding at December 31 109,419 170,726
Summary of options to service providers were measured at the fair value of the service	2018 2017 2016 Share Price - USD 1.18 1.82 - 2.17 1.06 - 1.348 Option price - USD 0.80 3.28 - 3.82 21.38 - 28.40 Expected volatility (%) 105.77 80.65 - 80.91 - Expected duration (years) 4.95 6.77 - 6.97 4-8 Dividend yield (%) - - - Risk free rate interest rate (%) 1.41 % 1.36 - 1.39 N/A
Summary of share based expenses	For the year ended December 31 2018 2017 2016 USD thousands Research and development expenses 546 709 176 General and administrative expenses 227 1,570 224 Other expenses - 29 - Total share-based expense recognized 773 2,308 400
Binominal Model [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Summary of options to service providers were measured at the fair value of the service	2018 Share Price - USD 368.39 Option price - USD 369.39 Expected volatility (%) 79.16 Expected duration (years) 7 Dividend yield (%) - Risk free rate interest rate (%) 2.4 %

Transactions and Balances wit_2

Transactions and Balances with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2018
Executive Officers [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Schedule of payments to key management	For the year ended December 31 2018 2017 2016 USD thousands Short - term employee benefits 2,165 2,305 1,282 Post-employment benefits 16 137 25 Share based payments 574 1,669 244 2,755 4,111 1,551
Directors [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Schedule of payments to key management	For the year ended December 31 2018 2017 2016 USD thousands Short - term benefits 268 217 54 Share based payments 86 236 - 354 453 54

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingent Liabilities [Abstract]
Schedule of future minimum lease payments	2018 2017 USD thousands USD thousands Less than one year 195 202 Between one to five years 751 784 More than five years 360 584

Research and Development Expe_2

Research and Development Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Research and Development Expenses [Abstract]
Schedule of research and development expenses	For the year ended December 31 2018 2017 2016 USD thousands Salaries, wages and related expenses 933 969 493 Share-based payments (see also Note 10) 546 709 176 Service providers 3,789 2,962 3,511 5,268 4,640 4,180

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
General and Administrative Expenses [Abstract]
Schedule of of general and administrative expenses	For the year ended December 31 2018 2017 2016 USD thousands Employees and officers compensation 1,733 1,984 1,131 Share-based payments (see also Note 10) 87 1,224 121 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 12B) 690 893 84 Other professional consulting 1,525 1,306 1,059 Board member remuneration and insurance 556 552 155 Rent and office maintenance 243 196 94 Travel 143 131 99 Car expenses 85 64 42 Depreciation 7 4 2 Other 126 (*)43 216 5,195 6,397 3,003 (*) Restated due to full retrospective method of adoption of IFRS 15 , Revenue from Contracts with Customers,

Finance Expense (Income) (Table

Finance Expense (Income) (Tables)	12 Months Ended
	Dec. 31, 2018
Finance Expense (Income) [Abstract]
Schedule of net change in fair value of derivatives	For the year ended December 31 2018 2017 2016 USD thousands Net change in fair value of derivatives Expenses - 1,049 5,160 Income (2,740 ) - (141 ) Net change in fair value of derivatives (*) (2,740 ) 1,049 5,019 (*) The derivatives are related to the fair value adjustments of warrants. Warrants issued in 2016 and 2017 included an anti-dilution provision whereby the exercise price of the warrants were subject to “weighted average” ratchet anti-dilution provision, so that upon future issuance of the Company’s ADSs, subject to specified exceptions, at a price less than the exercise price then in effect, the exercise price will be reduced. The ratchet for the 2017 warrants expired on January 14, 2018, and the ratchet for the 2016 Series A warrants expired on November 25, 2016. The 2017 warrants included a cashless exercise feature, which expired on August 8, 2018 when the Company filed a registration statement with the SEC, registering the shares that will derive from future exercise of these warrants. The 2018 warrants include a cashless exercise feature (See Note 20B).
Schedule of financing expenses (Income)	For the year ended December 31 2018 2017 2016 USD thousands Finance expense Fees and interest expense 9 26 6 Loss from exchange rate differences, net 106 - 55 Payment to Taoz, see Note 5D 160 - - Warrant issuance costs 301 - - 576 26 61 For the year ended December 31 2018 2017 2016 USD thousands Finance income Income from exchange rate differences, net - (22 ) - Interest income from short term deposits (93 ) (106 ) (138 ) (93 ) (128 ) (138 )

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2018
Employee Benefits [Abstract]
Schedule of post-employee benefits	Year ended December 31 2018 2017 USD thousands USD thousands Short-term benefits 136 112 Post-employment benefits 405 492
Schedule of defined contribution plan in respect of its employees	Year ended December 31 2018 2017 2016 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 95 52 39

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Financial Instruments [Abstract]
Schedule of sensitivity test to possible changes in USD/NIS exchange rate	Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 15 38 754 (38 ) (15 ) Other current assets 3 7 135 (7 ) (3 ) Accounts payable (6 ) (16 ) (312) 16 6 Other payables (29 ) (71 ) (1,425) 71 29 Post-employment benefit liabilities (5 ) (12 ) (235) 12 5 Total income (loss) (22 ) (54 ) 54 22
Schedule of financial instruments measured at fair value	December 31, 2018 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9D(1)) - - 554 554 December 31, 2017 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9D(2)) - - 2,012 2,012 Put option to Taoz (see Note 5B) - - 1,030 1,030 - - 3,042 3,042
Schedule of fair value measurement	Financial instrument Valuation method for determining fair value Significant unobservable inputs As of December 31, 2018 Warrants Black - Scholes expected term 4.9 years expected volatility 97.29 % annual risk free interest 2.51 % dividend yield 0 % As of December 31, 2017 Warrants Black - Scholes expected term 5.5 years expected volatility 81.66 % annual risk free interest 1.94 % dividend yield 0 % Investment and Put option to Taoz Monte–Carlo Simulation Valuation at milestone (USD thousand) 12,000 – 17,000 Share Price (USD) 812 – 1,150 Probability of reaching milestone (%) 50 % Risk free interest rate (%) 1.71% - 1.97% expected volatility 74.96 %

Significant Accounting Polici_3

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies (Textual)
Lease liability, description	These changes are expected to result in an increase of USD 1.2 million in the balance of right-of-use assets at the date of initial application and an increase of USD 1.2 million in the balance of the lease liability at the date of initial application.
Nominal discount rate used for measuring lease liability	8.00%

General (Details)

General (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2019	Nov. 30, 2015	Dec. 31, 2018	Dec. 31, 2017	[1]
Disclosure of non-adjusting events after reporting period [line items]
Accumulated deficit			$ (43,672)	$ (38,472)
Fund raised for current development plans			$ 39,700
Description of warrants to purchase ADS		Each ADS represents 1 ordinary share with no par value following a reverse split in effect from January 4, 2019 (see note 9A). Each warrant enables the purchase of 1 ADS.
Announcement of plan to discontinue operation [member]
Disclosure of non-adjusting events after reporting period [line items]
Fund raised for current development plans	$ 5,400
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

Basis of Preparation of the F_3

Basis of Preparation of the Financial Statements (Details) - Bank of Israel [Member] - NIS	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Foreign Exchange Rates [Line Items]
Representative exchange rate of USD (NIS/USD 1)	3.748	3.467	3.845
Changes in exchange rates for the Year ended	8.10%	(9.80%)	(1.50%)

Basis of Preparation of the F_4

Basis of Preparation of the Financial Statements (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accumulated loss	$ (43,672)	$ (38,472)	[1]
According to the previous policy [Member]
Accumulated loss		(38,567)
Deferred income		95
The change [Member]
Accumulated loss		95
Deferred income		(95)
According to IFRS 15 [Member]
Accumulated loss		(38,742)
Deferred income
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

Basis of Preparation of the F_5

Basis of Preparation of the Financial Statements (Details 2) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Revenues		$ 1,000	$ 100	[1]
General and administrative expenses		5,195	6,397	[1]	3,003
Operating Loss		(7,826)	(11,966)	[1]	(7,183)
Loss for the year		$ (5,569)	$ (12,913)	[1]	$ (12,125)
Impact on basic and diluted loss per share data :
Basic and diluted loss per share - USD		$ 0.39	$ 1.37	[2]	$ 2.11	[2]
According to the previous policy [Member]
Revenues			$ 0
General and administrative expenses			6,392
Operating Loss			12,061
Loss for the year			$ 13,008
Impact on basic and diluted loss per share data :
Basic and diluted loss per share - USD	[2]		$ 1.39
The change [Member]
Revenues			$ (100)
General and administrative expenses			5
Operating Loss			(95)
Loss for the year			$ (95)
Impact on basic and diluted loss per share data :
Basic and diluted loss per share - USD			$ (0.02)
According to IFRS 15 [Member]
Revenues			$ (100)
General and administrative expenses			6,397
Operating Loss			11,966
Loss for the year			$ 12,913
Impact on basic and diluted loss per share data :
Basic and diluted loss per share - USD			$ 1.37
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).
[2]	Restated to reflect a 20:1 reverse share split, that took place in January 2019, see Note 9A.

Basis of Preparation of the F_6

Basis of Preparation of the Financial Statements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Deferred revenue	$ 1,000	$ 100	[1]
Net of costs	5,195	6,397	[1]	$ 3,003
Retained earnings	$ (43,672)	(38,472)	[1]
According to IFRS 15 [Member]
Deferred revenue		(100)
Net of costs		6,397
Retained earnings		(38,742)
The change [Member]
Deferred revenue		(100)
Net of costs		5
Retained earnings		$ 95
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

Operating Segments (Details)

Operating Segments (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues		$ 1,000	$ 100	[1]
Research and development expenses		5,268	4,640		4,180
Operating Loss		(7,826)	(11,966)	[1]	(7,183)
Finance income, net		(2,257)	947		4,942
Loss for the year		(5,569)	(12,913)	[1]	$ (12,125)
Pain And Hypertension [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues		1,000	100
Research and development expenses		2,185	2,603
Operating Loss		4,730	6,674
Finance income, net
Loss for the year
Oncology [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues		0	0
Research and development expenses		2,537	1,328
Operating Loss		3,217	1,951
Finance income, net
Loss for the year
Total Reportable Segments [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues		1,000	100
Research and development expenses		4,722	3,931
Operating Loss		7,947	8,625
Finance income, net
Loss for the year
Reconciliations [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	[2]	0	0
Research and development expenses	[2]	546	709
Operating Loss	[2]	(121)	3,341
Finance income, net	[2]
Loss for the year	[2]
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).
[2]	Includes employees share based expenses and other expenses/income related to rights granted to Taoz.

Operating Segments (Details Tex

Operating Segments (Details Textual)	12 Months Ended
	Dec. 31, 2018SegmentsCustomers	Dec. 31, 2017Customers
Operating Segments [Abstract]
Number of reportable segments | Segments	2
Number of customers | Customers	1	1

Subsidiary (Details)

Subsidiary (Details) $ in Thousands	Jan. 13, 2017USD ($)
Summary of acquisition date fair value of each major class of consideration:
Cash	$ 2,000
Equity instruments issued (564,625 Ordinary Shares) (1)	1,800	[1]
Assignment of loan to the Company	(101)
Total consideration transferred	$ 3,699
[1]	The fair value of the Ordinary Shares issued was based on the listed share price of the Group on January 11, 2017 of approximately USD 3.19 per share

Subsidiary (Details 1)

Subsidiary (Details 1) $ in Thousands	Jan. 13, 2017USD ($)
Summary of recognized amounts of assets acquired and liabilities assumed at the date of acquisition:
Current assets	$ 21
Fixed assets, net	3
Intangible assets	6,172	[1]
Short-term credit from bank	(16)
Trade payables	(123)
Other payables	(212)
Long-term related parties	(130)
Total net identifiable assets	$ 5,715
[1]	In-process research and development

Subsidiaries (Details 2)

Subsidiaries (Details 2) - TyrNovo Ltd [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Disclosure of subsidiaries [line items]
Name of subsidiary	TyrNovo Ltd.
Country of incorporation of subsidiary	Israel
Group's ownership equity	97.60%
Company's direct ownership of equity	97.60%
Amounts provided by the Company to the subsidiary Loan	$ (2,366)
Total investment in subsidiary	$ 2,055

Subsidiary (Details Textual)

Subsidiary (Details Textual) - USD ($)	Jan. 13, 2017	Dec. 31, 2018	Jun. 30, 2018	Oct. 31, 2017	Jan. 11, 2017
Subsidiary (Textual)
Cash proceeds	$ 2,000,000
Percentage of ordinary shares acquired			4.10%	27.00%
Ordinary shares issued	564,625		140,845
Cash consideration paid	$ 167
Fair value of ordinary shares issued price per share					$ 3.19
ADS [Member]
Subsidiary (Textual)
Ordinary shares issued				658,484
TyrNovo [Member]
Subsidiary (Textual)
Cash proceeds	$ 2,000,000
Percentage of ordinary shares acquired	65.00%
Ordinary shares issued	9,570
Loans	$ 101,000
GHP [Member]
Subsidiary (Textual)
Cash proceeds		$ 76,000
Ordinary shares issued	564,625
Cash consideration paid		$ 91,000

Subsidiary (Details Textual 1)

Subsidiary (Details Textual 1) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Jun. 30, 2018	Feb. 09, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Oct. 31, 2017
Subsidiary [Abstract]
Name of acquiree		TyrNovo
Description of acquiree		A shareholder owning at that time approximately 4% of TyrNovo, entered into a settlement arrangement in response to a motion filed by Taoz on January 19, 2017.
Measurement of issued and outstanding share capital, description		Taoz was entitled to be issued an additional 77 ordinary shares of TyrNovo, representing 0.5% of the issued and outstanding share capital of TyrNovo immediately following this issuance. The shares were issued in February 2017 and were measured at a fair value of USD 29 thousand.
Description of measurement basis for non-controlling interest in acquiree recognised at acquisition date		Taoz had the right during a defined period to invest an additional USD 1,750,000 (the "Deferred Investment") by way of convertible loans, with conversion terms defined under various circumstances, including the possibility of conversion at a price per share reflecting a 30% discount off the price per share paid in a subsequent financing round, and the possibility of conversion at a price per TyrNovo share reflecting a TyrNovo company valuation of USD 13,500,000.
Percentage of voting equity interests acquired	4.10%					27.00%
Provided to Taoz a put option to sell, description		The Company provided to Taoz a put option to sell to the Company up to 50% of the TyrNovo shares issued to Taoz, exercisable during a period of 90 days from the publication by TyrNovo of the results of Phase I clinical trials, for a price per TyrNovo share equal to USD 1,600, either in ordinary shares of the Company or, at the Company' sole discretion, in cash; upon the expiration of the 90 day exercise period, the put option, if not exercised by Taoz, shall expire and no longer be valid.
Rights granted, share options granted		$ 1,000		$ 1,030
other expenses				29
Finance expense	$ 160	$ 30	$ 576	$ 26	$ 61
Price per share		$ 476.48

Subsidiary (Details Textual 2)

Subsidiary (Details Textual 2) - USD ($) $ in Thousands	1 Months Ended				12 Months Ended
	Jun. 30, 2018	Jun. 15, 2018	Oct. 31, 2017	Feb. 09, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 13, 2017
Subsidiary Textual [Abstract]
Acquisition of additional stake percentage			27.00%
Percentage of ordinary shares acquired	4.10%		27.00%
Held in ordinary shares			4,024
Percentage of issued and outstanding share capital			6.00%
Ordinary shares issued	140,845							564,625
Carrying amount of net assets on date of the acquisition	$ 1,977		$ 2,821
Decrease in non-controlling interests	93		768
Increase in share premium	237		1,483
Decrease in a capital reserve for transactions with non-controlling interest	144		$ 715
Percentage of issued and outstanding ordinary shares		97.40%	91.90%
Fair value of the shares issued in consideration for waving the rights amount	136
Derivative financial liabilities	1,030
Other income	894
Increase in share premium deriving from the waiving of the rights	136
Finance expense	$ 160			$ 30	$ 576	$ 26	$ 61
ADS [Member]
Subsidiary Textual [Abstract]
Ordinary shares issued			658,484

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 5,163	$ 3,947	$ 6,758	$ 10,558
Balance in USD [Member]
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	4,410	3,322
Balance in other currencies [Member]
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 753	$ 625

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Current Assets [Abstract]
Government authorities	$ 81	$ 171
Reimbursement of legal fees receivable	743	0
Prepaid fee to the Food and Drug Administration	930	0
Prepaid expenses and other receivables	76	377	[1]
Total other current assets	$ 1,830	$ 548
[1]	Including an amount of USD 166 thousand, representing deposits entrusted to Israeli court on behalf of related parties pursuant to an indemnification obligation of the Company, in respect of an investigation of the Israeli Security Authority against the Company. See also Note 12B.

Other Current Assets (Details T

Other Current Assets (Details Textual) $ in Thousands	Dec. 31, 2017USD ($)
Other Current Assets (Textual)
Deposits	$ 166

Other Payables (Details)

Other Payables (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Payables [Abstract]
Due to related parties - payroll related	$ 910	$ 1,059
Due to GHP (Note 5A)	167	167
Accrued expenses	852	326
Government authorities	65	107
Payroll related payables	61	87
Other Payables Total	$ 2,055	$ 1,746	[1]
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

Equity (Details)

Equity (Details) - shares	Dec. 31, 2018	Dec. 31, 2017
Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	250,000	250,000,000
Number of shares, Issued and paid-in	16,009	11,222,000
Class A preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000	10,000,000
Number of shares, Issued and paid-in
Class B preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000	10,000,000
Number of shares, Issued and paid-in
Class C preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000	10,000,000
Number of shares, Issued and paid-in
Class D preferred share [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000	10,000,000
Number of shares, Issued and paid-in
Class E preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	10,000	10,000,000
Number of shares, Issued and paid-in

Equity (Details 1)

Equity (Details 1) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Issued as at January 1	11,222	7,662	3,888
Issuance of ADSs (See D below)	3,260	2,432	2,379
Issuance of shares (See Note 5)	799	565	0
Share issuance deriving from a development agreement (See E6 below)	0	0	151
Share based payments	121	563	33
Exercise of warrants	607	0	1,211
Issued as at December 31	16,009	11,222	7,662

Equity (Details 2)

Equity (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Noncontrolling Interests [Line Items]
Current assets	$ 8,514	$ 7,983
Current liabilities	3,314	3,973
Loss allocated to non-controlling interests	$ 369	$ 736
Non-controlling interests [member] | TyrNovo Ltd. [Member]
Noncontrolling Interests [Line Items]
Non-controlling interests percentage	2.40%	35.28%
Non-current assets	$ 9	$ 3
Current assets	415	158
Current liabilities	(4,120)	(2,676)
Net assets	(3,696)	(2,515)
Net assets attributable to non-controlling interests	(89)	(887)
Loss for the year	3,688	2,088
Loss allocated to non-controlling interests	$ 369	$ 736

Equity (Details Textual)

Equity (Details Textual) - USD ($)	Dec. 31, 2018	Oct. 30, 2017	Jun. 30, 2018	Dec. 31, 2017	Oct. 31, 2017	Jul. 31, 2017	Jul. 31, 2016	May 31, 2016	Nov. 30, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 09, 2017
Disclosure of classes of share capital [line items]
Placement agent fees and other offering related expenses										$ 1,525,000	$ 1,306,000	$ 1,059,000
Public offering price per unit														$ 476.48
Description of warrants rights										During the reported year 343 thousand warrants, issued in July 2017, were exercised into 343 thousand shares for a consideration of USD 515 thousand. In addition, 484 thousand warrants, issued in July 2017, were exercised into 264 thousand shares on a cashless exercise, and an amount of USD 1,618 thousand was recorded to share premium against derivative liabilities.
Shares to service providers for services granted												669,100
Shares to service providers for services granted, value												$ 103,000
General and administrative expenses											6,333,000	$ 3,003,000	$ 1,509,000
Company issued securities, description	The Company's authorized and paid-in share capital in a 20:1 ratio, in a way that every 20 shares with no par value were consolidated into one share with no par value. The said reverse share split took place on January 4, 2019. Following the reverse share split, the Company's authorized share capital is 250,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class.
Ordinary shares restricted stock units										$ 121,000
Ordinary share [Member]
Disclosure of classes of share capital [line items]
Shares to service providers for services granted												33,455
Shares to service providers for services granted, value												$ 103,000
Ordinary shares of vested restricted stock units				496,533	496,533
Dexcel Ltd. [Member]
Disclosure of classes of share capital [line items]
Shares to service providers for services granted								150,494
Shares to service providers for services granted, value								$ 500
Series A warrant [Member]
Disclosure of classes of share capital [line items]
Public offering issued by securities									3,158,900
Warrants to purchase shares of common stock							2,378,823
Shares to service providers for services granted												1,211,306
Proceeds from exercise of warrants												$ 302,000
Direct Offering [Member]
Disclosure of classes of share capital [line items]
Company funds raised						$ 3,500,000
Placement agent fees and other offering related expenses						$ 3,100,000
Public Offering [Member]
Disclosure of classes of share capital [line items]
Company funds raised			$ 8,100,000				$ 12,000,000
Placement agent fees and other offering related expenses			$ 7,400,000				$ 10,000,000
Public offering price							$ 3.40
Company issued securities, description							(i) 2,378,823 Class A units - comprised of 2,378,823 ADSs and 2,378,823 Series A warrants to purchase 2,378,823 ADSs, and (ii) 1,150,589 Class B units - comprised of 1,150,589 prefunded Series B warrants to purchase 1,150,589 ADSs and 1,150,589 Series A warrants to purchase 1,150,589 ADSs
ADS [Member]
Disclosure of classes of share capital [line items]
Concurrent private placement issued			3,260,000			2,431,746
Public offering price
Warrant exercise price			$ 2.80			$ 1.50	$ 4.08
Warrants to purchase shares of common stock			1,630,000			1,215,873	141,176
Adjusted value of warrants			$ 3,467,000
Shares to service providers for services granted		67,367
Shares to service providers for services granted, value		$ 150,000
General and administrative expenses										$ 54,000	96,000
Non-listed warrants			1,630,000			1,215,873
Issue of equity			$ 4,276,000								$ 2,174,000
Finance expenses			$ 301,000
ADS [Member] | Series A warrant [Member]
Disclosure of classes of share capital [line items]
Warrant exercise price							$ 3.78
Warrants to purchase shares of common stock							2,378,823
ADS [Member] | Series B warrant [Member]
Disclosure of classes of share capital [line items]
Warrant exercise price							$ 0.01

Share-based Payment Arrangeme_3

Share-based Payment Arrangements (Details) - $ / shares		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Weighted average exercise prices (in USD)
Outstanding at January 1	[1]	$ 3.08	$ 4.29	$ 4.86
Expired during the year	[1]	7	20.72	4.16
Granted during the year	[1]	1.59	1.85	4.05
Outstanding at December 31	[1]	2.60	3.08	4.29
Exercisable at December 31	[1]	$ 2.95	$ 2.83	$ 3.31
Number of options
Outstanding at January 1		1,002,021	519,746	175,536
Expired during the year		30,000	2,239	143,297
Granted during the year		159,759	484,515	487,507
Outstanding at December 31		1,131,780	1,002,021	519,746
Exercisable at December 31		873,344	708,879	113,490
[1]	The exercise price is denominated in NIS and are re-measured using historic exchange rates.

Share-based Payment Arrangeme_4

Share-based Payment Arrangements (Details 1) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of RSUs
Outstanding at January 1	170,727
Granted during the year	59,720	13,345,205
Vested during the year	121,028	(9,930,671)
Outstanding at December 31	109,419	170,727

Share-based Payment Arrangeme_5

Share-based Payment Arrangements (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD	$ 1.18
Option price - USD	$ 0.80
Expected volatility (%)	105.77%
Expected duration (years)	4 years 11 months 12 days
Dividend yield (%)
Risk free rate interest rate (%)	1.41%
Binominal Model [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD	$ 368.39
Option price - USD	$ 369.39
Expected volatility (%)	79.16%
Expected duration (years)	7 years
Dividend yield (%)
Risk free rate interest rate (%)	2.40%
Minimum [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD		$ 1.82	$ 1.06
Option price - USD		$ 3.28	$ 21.38
Expected volatility (%)		80.65%
Expected duration (years)		6 years 9 months 7 days	4 years
Risk free rate interest rate (%)		1.36%
Maximum [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - USD		$ 2.17	$ 1.348
Option price - USD		$ 3.82	$ 28.40
Expected volatility (%)		80.91%
Expected duration (years)		6 years 11 months 19 days	8 years
Risk free rate interest rate (%)		1.39%

Share-based Payment Arrangeme_6

Share-based Payment Arrangements (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Share-based Payment Arrangements [Abstract]
Research and development expenses	$ 5,268	$ 4,640		$ 4,180
General and administrative expenses	5,195	6,397	[1]	3,003
Other expenses		29
Total share-based expense recognized	$ 773	$ 2,308		$ 400
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

Share-based Payment Arrangeme_7

Share-based Payment Arrangements (Details Textual) $ / shares in Units, $ in Thousands

Nov. 20, 2018USD ($)$ / sharesshares

Jan. 03, 2018USD ($)shares

Aug. 15, 2017USD ($)Consultants$ / sharesshares

Aug. 01, 2017USD ($)$ / sharesshares

Aug. 31, 2017

Jun. 30, 2017shares

Jun. 30, 2016USD ($)$ / sharesshares

May 31, 2016shares

May 22, 2016

Nov. 25, 2015

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2017USD ($)$ / sharesshares

Dec. 31, 2016$ / sharesshares

Jan. 03, 2017shares

Dec. 31, 2015shares

Dec. 31, 2014shares

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

16,009,000

11,222,000

7,662,000

153,237,000

3,888,000

5,972,000

Vesting period

3 years

Exercise period

7 years

Fair value expense | $

$ 2,196

Options exercise price | $ / shares

$ 4.07

Fair value of options and grants measured | $

$ 2,071

Additional ordinary shares

1,900,000

Weighted average remaining contractual life

5 years 3 months 15 days

7 years 2 months 12 days

7 years 8 months 12 days

Key management personnel, description

The Company recorded an expense of USD 719 thousand USD (2017 - 2,196 thousand), of which USD 660 thousand (2017 - USD 1,905 thousand) are to key management personnel.

Top of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | $ / shares

$ 4.39

$ 7.01

$ 4.07

Bottom of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | $ / shares

$ 1.59

$ 1.84

$ 4.04

May 22, 2016 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Fully vested grant

28,000

Fair value of options and grants measured | $

$ 76

RSUs [Member] | November 25, 2015 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

8,000

Fair value of options and grants measured | $

$ 15

Board of Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | $ / shares

$ 1.85

Fair value of options and grants measured | $

$ 680

Number of grant option shares

123,438

Board of Directors [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

348,000

12,161,000

Additional number of shares issued

42,000

Board of Directors [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

580,000

8,790,000

Additional number of shares issued

16,000

Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

297,874

297,874

Term of vesting share options

8 years

8 years

Chairman of Board of Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | $ / shares

$ 4.39

$ 4.04

Number of grant option shares

364,069

364,069

Term of vesting share options

3 years

Number of consultants | Consultants

2

Service Provider [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Options exercise price | $ / shares

$ 1.84

Number of grant option shares

364,069

364,069

Number of consultants | Consultants

1

Service Provider [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

9,000

Fair value of options and grants measured | $

$ 32

Service Provider [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

29,000

Fair value of options and grants measured | $

$ 31

Directors and Officers [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Directors and Officers [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

22,000

Fair value of options and grants measured | $

$ 1,326

Directors and Officers [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

20,000

Fair value of options and grants measured | $

$ 592

Chief Executives Officer [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

364,069

364,069

Chief Financials Officer [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

364,069

364,069

Senior Employees [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

364,069

364,069

Offeree [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

5 years

Options exercise price | $ / shares

$ 1.59

Fair value of options and grants measured | $

$ 127

Offeree [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

34,825

Fair value of options and grants measured | $

$ 71

Two Executives [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

59,720

Two Executives [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

159,759

TyrNovo [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Exercise period

7 years

Key management personnel | $

$ 431

Fair value of options and grants measured | $

$ 431

Number of grant option shares

1,170

Share-based compensation expense | $

$ 402

Transactions and Balances wit_3

Transactions and Balances with Related Parties (Details) - Payments to Key Management [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Executive Officers [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short - term employee benefits	$ 2,165	$ 1,282	$ 2,305
Post-employment benefits	16	25	137
Share based payments	574	244	1,669
Total	2,755	1,551	4,111
Directors [Member]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short - term employee benefits	268	217	54
Share based payments	86	236
Total	$ 354	$ 453	$ 54

Commitments and Contingent Li_3

Commitments and Contingent Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Less than one year [Member]
Disclosure of contingent liabilities [line items]
Future minimum lease payments under non-cancellable operating leases	$ 195	$ 202
Between one to five years [Member]
Disclosure of contingent liabilities [line items]
Future minimum lease payments under non-cancellable operating leases	751	784
More than five years [Member]
Disclosure of contingent liabilities [line items]
Future minimum lease payments under non-cancellable operating leases	$ 360	$ 584

Commitments and Contingent Li_4

Commitments and Contingent Liabilities (Details Textual) $ in Thousands, ₪ in Millions

Nov. 08, 2016

Jul. 31, 2018USD ($)

Mar. 20, 2017

Feb. 28, 2017USD ($)

Feb. 28, 2017ILS (₪)

Feb. 10, 2017

Feb. 07, 2017

Dec. 31, 2018USD ($)

Dec. 31, 2018ILS (₪)

Dec. 31, 2017USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2015ILS (₪)

Commitments and Contingent Liabilities (Textual)

Bonus amount

$ 777

$ 1,056

Liability due to grants

405

492

Motion total amount

$ 4,300

₪ 16.4

Description, of lawsuit filing

The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion.

The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion.

Loss contingency actions taken by court arbitrator or mediator

The Motion to be excluded from the purported class and claiming to have independent causes of action and claims of approximately NIS 1 million (USD 262 Thousand) (the ''Petition to Exclude''). The Company responded to the court as required, and, amongst other arguments, the Company noted that such shareholder cannot petition to be excluded from the purported class. The court ordered the shareholder to respond and he has done so. In May 2018 the shareholder submitted an independent lawsuit against the Company in the Haifa Magistrates Court seeking damages of approximately NIS 1.1 million (USD 306 Thousand) (the ''Separate Lawsuit'').

Gains on litigation settlements

$ 8,000

₪ 29

Debt instrument offering date

Nov. 20, 2015

Nov. 20, 2015

Nov. 20, 2015

Leases bank guarantee fee

$ 46

$ 50

Aggregate consideration received

$ 2,000

Insurance carriers

$ 2,000

Bottom of range [member]

Commitments and Contingent Liabilities (Textual)

Annual interest rate of revenues

3.00%

3.00%

Top of range [member]

Commitments and Contingent Liabilities (Textual)

Annual interest rate of revenues

6.00%

6.00%

TyrNovo [Member] | Israel Innovation Authority [Member]

Commitments and Contingent Liabilities (Textual)

Maximum royalty payable excluding interest amount

$ 1,500

₪ 5.5

Yissum [Member]

Commitments and Contingent Liabilities (Textual)

Description of license agreement

In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales.(ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.

In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales.(ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.

Research and Development Expe_3

Research and Development Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Research and Development Expenses [Abstract]
Salaries, wages and related expenses	$ 933	$ 969	$ 493
Share-based payments	546	709	176
Service Providers Expenses	3,789	2,962	3,511
Research and development expense	$ 5,268	$ 4,640	$ 4,180

General and Administrative Ex_3

General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
General and Administrative Expenses [Abstract]
Employees and officers compensation	$ 1,733	$ 1,984		$ 1,131
Share-based payments (see also Note 10)	87	1,224		121
Legal fees in connection with ISA investigation and class action lawsuits (see also Note 12B)	690	893		84
Other professional consulting	1,525	1,306		1,059
Board member remuneration and insurance	556	552		155
Rent and office maintenance	243	196		94
Travel	143	131		99
Car expenses	85	64		42
Depreciation	7	4		2
Other	126	43	[1]	216
General and Administrative Expenses	$ 5,195	$ 6,397		$ 3,003
[1]	Restated due to full retrospective method of adoption of IFRS 15, Revenue from Contracts with Customers, see Note 2E(2).

General and Administrative Ex_4

General and Administrative Expenses (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
General and Administrative Expenses (Textual)
legal expenses	$ 743

Other Expenses (Income) (Detail

Other Expenses (Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other Expenses (Income) (Textual)
Other expenses (income)	$ (894)	$ 1,029

Finance Expense (Income) (Detai

Finance Expense (Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net change in fair value of derivatives
Expenses		$ 1,049	$ 5,160
Income	(2,740)		(141)
Net change in fair value of derivatives	$ (2,740)	$ 1,049	$ 5,019

Finance Expense (Income) (Det_2

Finance Expense (Income) (Details 1) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jun. 30, 2018	Feb. 09, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Finance expense
Fees and interest expense			$ 9	$ 26	$ 6
Loss from exchange rate differences, net			106		55
Payment to Taoz, see Note 5D			160
Warrant issuance costs			301
Finance expense	$ 160	$ 30	576	26	61
Finance income
Income from exchange rate differences, net				(22)
Interest income from short term deposits			(93)	(106)	(138)
Finance income			$ (93)	$ (128)	$ (138)

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Taxes on Income (Textual)
Unrecognized research and development expenses	$ 33.1	$ 28.2	$ 13.2
Corporate Tax Rate [Member]
Taxes on Income (Textual)
Corporate tax rate	23.00%	24.00%

Employee Benefits (Details)

Employee Benefits (Details) - Post-employment benefits [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short-term benefits	$ 136	$ 112
Post-employment benefits	$ 405	$ 492

Employee Benefits (Details 1)

Employee Benefits (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Benefits [Abstract]
Amount recognized as expense in respect of defined contribution plan	$ 95	$ 52	$ 39

Financial Instruments (Details)

Financial Instruments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Down 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	$ (22)
Down 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(54)
Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	54
Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	22
Cash and cash equivalents and deposits [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	754
Cash and cash equivalents and deposits [Member] | Down 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	15
Cash and cash equivalents and deposits [Member] | Down 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	38
Cash and cash equivalents and deposits [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(38)
Cash and cash equivalents and deposits [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(15)
Other current assets [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	135
Other current assets [Member] | Down 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	3
Other current assets [Member] | Down 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	7
Other current assets [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(7)
Other current assets [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(3)
Accounts payable [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	(312)
Accounts payable [Member] | Down 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(6)
Accounts payable [Member] | Down 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(16)
Accounts payable [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	16
Accounts payable [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	6
Other payables [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	(1,425)
Other payables [Member] | Down 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(29)
Other payables [Member] | Down 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(71)
Other payables [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	71
Other payables [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	29
Post-employment benefit liabilities [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) value	(235)
Post-employment benefit liabilities [Member] | Down 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(5)
Post-employment benefit liabilities [Member] | Down 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	(12)
Post-employment benefit liabilities [Member] | Up 5% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	12
Post-employment benefit liabilities [Member] | Up 2% [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
Income (loss) from change in exchange rate	$ 5

Financial Instruments (Details

Financial Instruments (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of fair value measurement of equity [line items]
Warrants	$ 554	$ 2,012
Put option to Taoz (see Note 5B)		1,030
Financial liabilities		3,042
Level 1 [Member]
Disclosure of fair value measurement of equity [line items]
Warrants
Put option to Taoz (see Note 5B)
Financial liabilities
Level 2 [Member]
Disclosure of fair value measurement of equity [line items]
Warrants
Put option to Taoz (see Note 5B)
Financial liabilities
Level 3 [Member]
Disclosure of fair value measurement of equity [line items]
Warrants	$ 554	2,012
Put option to Taoz (see Note 5B)		1,030
Financial liabilities		$ 3,042

Financial Instruments (Detail_2

Financial Instruments (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Warrants [Member] | Black - Scholes [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
expected term	4 years 10 months 25 days	5 years 6 months
expected volatility	97.29%	81.66%
annual risk free interest	2.51%	1.94%
dividend yield	0.00%	0.00%
Investment and Put option to Taoz [Member] | Monte - Carlo Simulation [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
expected volatility		74.96%
Probability of reaching milestone		50.00%
Investment and Put option to Taoz [Member] | Monte - Carlo Simulation [Member] | Top of range [member]
Disclosure of continuing involvement in derecognised financial assets [line items]
annual risk free interest		1.97%
Valuation at milestone		$ 17,000
Share Price		$ 1,150
Investment and Put option to Taoz [Member] | Monte - Carlo Simulation [Member] | Bottom of range [member]
Disclosure of continuing involvement in derecognised financial assets [line items]
annual risk free interest		1.71%
Valuation at milestone		$ 12,000
Share Price		$ 812

Financial Instruments (Detail_3

Financial Instruments (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Financial Instruments (Textual)
Cash and cash equivalents and short term deposits	$ 6,684	$ 7,435
Bottom of range [member]
Financial Instruments (Textual)
Short term deposits fixed interest rate	0.02%
Top of range [member]
Financial Instruments (Textual)
Short term deposits fixed interest rate	2.87%

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)
March 2019 [Member]
Subsequents Event (Textual)
Options to granted, description	The board of directors of the Company approved the grant of 3,132,895 options to directors, employees and consultants, exercisable to 3,132,895 ordinary shares with no par value of the Company, out of which 2,086,529 options to be granted to directors are subject to shareholders' approval.
ADS [Member] | January 2019 [Member]
Subsequents Event (Textual)
Direct offering description	The Company issued 3,428,572 ADSs and, in a concurrent private placement, 2,571,430 non-listed warrants to purchase 2,571,430 ADSs. Each non-listed warrant is exercisable until July 18, 2024 at an exercise price of USD 2.00 per ADS. The warrant holders have the option to exercise cashless.
NASDAQ [Member] | January 2019 [Member]
Subsequents Event (Textual)
Gross amount of placement agent fees	$ 6
Net of placement agent fees and other offering related expenses	$ 5.4
Coeptis Pharmaceuticals Inc. [Member] | January 2, 2019 [Member]
Subsequents Event (Textual)
Agreement description	The agreement provides for total milestone payments from Coeptis to the Company of USD 3.5 million, of which the initial milestone of USD 1 million was received upon execution of the agreement, and additional milestone payments are due upon completion of an agreed Chemistry, Manufacturing, Control (CMC) plan and upon first commercial sales in the U.S. In addition, the Company will be paid 40%-60% of Coeptis' net profit on Consensi sales.
Famewave Ltd [Member] | March 14, 2019 [Member]
Subsequents Event (Textual)
Agreement to acquire description	If no such commercialization transaction is consummated within 36 months from termination, Company will be entitled to 20% of FameWave in return for the approximately $2 million loan which was previously provided. Furthermore, should the transaction not close due to the failure of FameWave to finalize the clinical collaboration agreement, or the failure of certain other closing conditions to be fulfilled by the current shareholders of FameWave, then the Company will be entitled to 100% of FameWave in return for the approximately $2 million loan which was previously provided
Famewave Ltd [Member] | ADS [Member] | March 14, 2019 [Member]
Subsequents Event (Textual)
Agreement to acquire description	The Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM-24, ("FameWave) from its shareholders in exchange for $10 million worth of its newly issued ADSs with a long term lock-up period, priced at $1.23 per ADS, plus 50% warrant coverage based on an exercise price of $1.98 per ADS with a 4-year term. In addition, the Company will provide a loan to FameWave of up to approximately $2 million to be paid to cCAM BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and Dohme Corp., known as "MSD" in Israel, which discovered CM-24, or to repay certain loans provided by FameWave's shareholders.